Luminex Corporation
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities
Exchange Act of 1934 (Amendment No.
)
Filed by the Registrant
þ
Filed by a Party other than the Registrant
o
Check the appropriate box:
|
|
|
o Preliminary
Proxy Statement |
|
|
o Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
þ Definitive
Proxy Statement
|
o Definitive
Additional Materials
|
o Soliciting
Material Pursuant to §240.14a-12
|
LUMINEX CORPORATION
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
þ |
No fee required.
|
|
o |
Fee computed on table below per Exchange Act
Rules 14a-6(i)(4) and 0-11.
|
|
|
(1) |
Title of each class of securities to which
transaction applies:
|
|
|
(2) |
Aggregate number of securities to which
transaction applies:
|
|
|
(3) |
Per unit price or other underlying value of
transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and
state how it was determined):
|
|
|
(4) |
Proposed maximum aggregate value of transaction:
|
|
|
o |
Fee paid previously with preliminary materials.
|
|
o |
Check box if any part of the fee is offset as
provided by Exchange Act Rule 0-11(a)(2) and identify the
filing for which the offsetting fee was paid previously.
Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
|
|
|
(1) |
Amount Previously Paid:
|
|
|
(2) |
Form, Schedule or Registration Statement No.:
|
TABLE OF CONTENTS
LUMINEX CORPORATION
12212 Technology Boulevard
Austin, Texas 78727
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held May 24, 2007
Luminex Corporation (the Company) will hold its 2007 annual meeting of stockholders (the
Meeting) on Thursday, May 24, 2007, at 10:00 a.m., local time, at the Hilton Austin Airport
Hotel, 9515 New Airport Drive, Austin, Texas 78719. At the Meeting, stockholders will act on the
following matters:
|
(1) |
|
election of three members to the Board of Directors to serve for three-year
terms as Class I Directors (designated as Proposal 1 in the accompanying proxy
statement); |
|
|
(2) |
|
ratification of the appointment by the Companys Audit Committee of Ernst &
Young LLP as the Companys independent registered public accounting firm for fiscal
2007 (designated as Proposal 2 in the accompanying proxy statement); and |
|
|
(3) |
|
such other business as may properly come before the Meeting or any adjournment
or postponement thereof. |
The Board of Directors has fixed the close of business on April 11, 2007 as the record date
for the determination of stockholders entitled to notice of, and to vote at, the Meeting or any
adjournment or postponement thereof. A complete list of such stockholders will be available for
examination at our offices in Austin, Texas, during normal business hours for a period of ten days
prior to the Meeting.
Your attention is directed to the proxy statement accompanying this notice for a more complete
statement regarding the matters to be acted upon at the Meeting. Our annual report to stockholders
is being mailed with this notice and proxy statement, but it is not part of the proxy solicitation
materials. All stockholders are cordially invited to attend the Meeting. However, stockholders
are urged, whether or not they plan to attend the Meeting, to either sign, date and mail the
enclosed proxy in the postage-paid envelope provided, or to vote by telephone or electronically
pursuant to the instructions included with the proxy.
By Order of the Board of Directors,
David S. Reiter
Vice President, General
Counsel and Corporate Secretary
Austin, Texas
April 23, 2007
LUMINEX CORPORATION
12212 Technology Boulevard
Austin, Texas 78727
PROXY STATEMENT
For Annual Meeting of Stockholders
To Be Held May 24, 2007
This proxy statement is being furnished to the stockholders of Luminex Corporation (the
Company, Luminex, we or us) in connection with the solicitation by the Board of Directors
of proxies for use at the 2007 annual meeting of stockholders (the Meeting) to be held at the
time and place and for the purposes set forth in the accompanying notice, and at any and all
adjournments or postponements thereof. The approximate date of the mailing of this proxy statement
and the accompanying proxy card is April 23, 2007.
Voting Procedures; General Information
Proposals 1 and 2 will be presented by management at the Meeting. With regard to Proposal 1,
the form of proxy permits votes for or withholding of votes as to all nominees for director or for
withholding votes for any specific nominee, and permits votes for, against, or abstention with
regard to Proposal 2. If the enclosed form of proxy is properly executed, returned, and not
revoked, it will be voted in accordance with the specifications, if any, made by the stockholder
and, if specifications are not made, will be voted FOR the nominees named in this proxy statement
to the Companys Board of Directors and FOR the ratification of the appointment of Ernst & Young
LLP as the Companys independent registered public accounting firm for fiscal 2007.
If your shares are held by your broker or other nominee, often referred to as in street
name, you will receive a form from your broker seeking instructions as to how your shares should
be voted. If you are a registered stockholder, you may vote by telephone or electronically through
the Internet by following the instructions included with your proxy card. If your shares are held
in street name, you should contact your broker or nominee to determine whether you will be able to
vote by telephone or electronically. If your shares are held in street name and you do not issue
instructions to your broker, your broker, under the rules of The Nasdaq Stock Market LLC, may vote
your shares in its discretion on routine matters, but may not vote your shares on non-routine
matters. The election of directors and the ratification of Ernst & Young LLP as our independent
registered public accounting firm for fiscal 2007 (Proposals 1 and 2) are both deemed routine
matters. Therefore, your broker has discretionary authority to vote your shares on such matters
absent specific instructions from you.
It is not expected that any matter not referred to herein will be presented for action at the
Meeting. If any other matters are properly brought before the Meeting, including, without
limitation, a motion to adjourn the Meeting to another time and/or place for the purpose of, among
other things, permitting dissemination of information regarding material developments relating to
any of the Proposals, or soliciting additional proxies in favor of the approval of any of the
Proposals, the persons named on the accompanying proxy card will vote the shares represented by
such proxy upon such matters in their discretion. Should the Meeting be reconvened, all proxies
will be voted in the same manner as such proxies would have been voted when the Meeting was
originally convened, except for the proxies effectively revoked or withdrawn prior to the time
proxies are voted at such reconvened meeting.
Any stockholder giving a proxy may revoke it at any time before it is voted by communicating
such revocation in writing to our Corporate Secretary at the address indicated above, by executing
and delivering a later-dated proxy or by voting in person at the Meeting.
Quorum; Required Votes and Recommendations
Our only outstanding voting security is our common stock. Holders of record of common stock
at the close of business on April 11, 2007, the record date for the Meeting, are entitled to notice
of and to vote at the Meeting. On the record date for the Meeting, there were 35,225,703 shares of
common stock outstanding and entitled to vote at the Meeting. In deciding all matters, a holder of
common stock on the record date shall be entitled to cast one vote for each share of common stock
then registered in such holders name or otherwise beneficially owned.
The holders of a majority of the outstanding shares of the Companys common stock as of the
record date must be present in person or be represented by proxy to constitute a quorum and act
upon the proposed business. Failure of a quorum to be represented at the Meeting will necessitate
an adjournment or postponement and will subject the Company to additional expense. Votes withheld
from any nominee for director and abstentions are counted as present or represented for purposes of
determining the presence or absence of a quorum.
Proposal 1 discussed in this Proxy Statement requires the affirmative vote of a plurality of
the votes cast at the Meeting. Accordingly, the three nominees receiving the highest number of
affirmative votes of the shares present or represented and entitled to vote at the Meeting shall be
elected as Class 1 directors. Proposal 2 requires the affirmative vote of the holders of a
majority of the outstanding shares represented at the Meeting and entitled to vote thereon. Votes
will be counted by the Companys transfer agent. Under Delaware law, abstentions are not counted
as voting for or against a particular matter. However, abstentions are included in the number
of shares present or represented at the Meeting and entitled to vote, and therefore, abstentions
will have the same effect as a vote cast against Proposal 2. Abstentions and withhold votes will
have no effect on the outcome of Proposal 1. Additionally, if a broker turns in a proxy card
expressly stating that the broker is not voting on a nonroutine matter, such action is referred to
as a broker nonvote. Broker nonvotes are counted for the purpose of determining the presence or
absence of a quorum, but are not counted for determining the number of votes cast, as a broker
nonvote is not considered entitled to vote on a matter. However, because the Proposals are each
routine matters, there will not likely be any broker nonvotes. Accordingly, broker nonvotes will
not impact the matters scheduled to be considered at the Meeting.
The Board of Directors unanimously recommends that you vote:
|
|
|
FOR the Class I Director nominees named in this proxy statement; and |
|
|
|
|
FOR the ratification of the appointment of Ernst & Young LLP as the Companys
independent registered public accounting firm for fiscal 2007. |
CORPORATE GOVERNANCE
We believe that effective corporate governance is critical to our long-term health and ability
to create value for our stockholders. Our Board of Directors believes that we have in place
appropriate charters, policies (including a comprehensive Code of Compliance and corporate
governance guidelines), procedures and controls that promote and enhance corporate governance,
accountability and responsibility with respect to the Company and a culture of honesty and
integrity. We will continue to monitor emerging developments and best practices in corporate
governance and augment these charters, policies, procedures and controls when required or when our
Board determines it would benefit the Company and our stockholders. Our corporate governance
policies, including our various Board committee charters, can be viewed at the Investor Relations
section of our website at www.luminexcorp.com. Information contained on our website is not
incorporated into this proxy statement by this or any other reference to our website in this proxy
statement, and we do not intend the information on or linked to our website to constitute part of
this proxy statement.
Director Independence
Our Board of Directors consults with the Companys counsel to ensure that the Boards
independence determinations are consistent with all relevant securities and other laws and
regulations regarding the definition of independent director, including but not limited to those
set forth in pertinent listing standards of the The Nasdaq Stock Market LLC as in effect from time
to time. To assist in the Boards independence determinations, each director completed materials
designed to identify any relationships that could affect the directors independence. In addition,
through discussion among the directors a subjective analysis of independence was reviewed. The
Board has determined that each of the following directors is an independent director consistent
with the objective requirements of applicable laws and regulations, and that such persons do not
otherwise have any relationship that, in the opinion of the Board of Directors, would interfere
with the exercise of such persons independent judgment in carrying out the responsibilities of a
director: Robert J. Cresci; Jim D. Kever; Fred C. Goad, Jr.; Jay B. Johnston; Gerard
Vaillant; Kevin M. McNamara and J. Stark Thompson. The Board has not established categorical
standards
2
or guidelines to make the subjective aspect of these determinations, but considers all relevant
facts and circumstances known to the Board.
Director Qualifications
The Nominating and Corporate Governance Committee may consider whatever factors it deems
appropriate in its assessment of a candidate for board membership; however, candidates nominated to
serve as directors will, at a minimum, in the committees judgment:
|
|
|
be able to represent the interests of the Company and all of its stockholders and not be
disposed by affiliation or interest to favor any individual, group or class of stockholders
or other constituency; and |
|
|
|
|
possess the background and demonstrated ability to contribute to the Boards performance
of its collective responsibilities, through senior executive management experience,
relevant professional or academic distinction, and/or a record of relevant civic and
community leadership. |
The consideration of a candidate for director will include the Nominating and Corporate
Governance Committees assessment of the individuals background, skills and abilities, and whether
such characteristics fulfill the needs of the Board of Directors at that time. As part of the
Nominating and Corporate Governance Committees consideration of a candidate, the committee also
believes that the candidate must:
|
|
|
be of high ethical character and share the core values of Luminex as reflected in our
Code of Compliance; |
|
|
|
|
have a reputation, both personal and professional, consistent with the image and reputation of Luminex; |
|
|
|
|
be highly accomplished in the candidates field; |
|
|
|
|
be an active or former chief executive officer of a public company or a biotechnology
company or an active or former leader of another complex organization; |
|
|
|
|
otherwise have relevant expertise and experience, and be able to offer advice and
guidance to the chief executive officer based on that expertise and experience; and/or |
|
|
|
|
have the ability to exercise sound business judgment. |
Process for Identifying Director Candidates
The Nominating and Corporate Governance Committee may utilize a variety of methods for
identifying nominees for director. Candidates may come to the attention of the Nominating and
Corporate Governance Committee through current Board members, professional search firms,
stockholders or other persons. The Nominating and Corporate Governance Committee considers
nominees proposed by the Companys stockholders in accordance with the provisions contained in our
bylaws. Pursuant to the our bylaws, any stockholder may nominate a person for election to our
Board of Directors, provided that the nomination is received by the Secretary of the Company not
less than 30 days nor more than 90 days prior to the first anniversary of the preceding years
Meeting. Each nomination submitted in this manner shall include the name and address of the
nominee(s) and all other information with respect to the nominee as required to be disclosed in the
proxy statement for the election of directors under applicable rules of the Securities and Exchange
Commission (SEC), including the nominees consent to being named as a nominee and to serving as a
director, if elected. Additionally, the nominating stockholder must provide his or her name and
address as it appears in the stock records of the Company and the number of shares of common stock
beneficially owned by the stockholder.
Evaluation of Director Candidates
The chair of the Nominating and Corporate Governance Committee will preliminarily assess a
candidates qualifications and suitability, working with management support and seeking board
input, and report such assessment to the Nominating and Corporate Governance Committee members.
When feasible, the chair of the Nominating and Corporate Governance Committee will interview
candidates whom the chair believes are likely to meet the criteria for board membership as part of
the preliminary assessment process. The report may be made to the Nominating and Corporate
Governance Committee at a meeting of the committee or informally to each committee member between
meetings.
3
If it is the consensus of the Nominating and Corporate Governance Committee that a candidate
is likely to meet the criteria for board membership, the chair of the committee will advise the
candidate of the committees preliminary interest. If the candidate expresses sufficient interest,
the committee will arrange interviews of the candidate with one or more members of the committee,
and request such additional information from the candidate as the committee deems appropriate. The
Nominating and Corporate Governance Committee will consider the candidates qualifications,
background, skills and abilities, and whether such characteristics fulfill the needs of the board
at that time, and confer and reach a collective assessment as to the qualifications and suitability
of the candidate for board membership.
If the Nominating and Corporate Governance Committee determines that the candidate is suitable
and meets the criteria for board membership, the candidate will be invited to meet with the senior
management of the Company and other members of the Board of Directors, both to allow the candidate
to obtain further information about the Company and to give management and the other directors a
basis for input to the Nominating and Corporate Governance Committee regarding the candidate. On
the basis of its assessment, and taking into consideration input from other Board members and
senior management, the Nominating and Corporate Governance Committee will formally consider whether
to recommend the candidates nomination for election to the Board of Directors.
Code of Compliance
We have a Code of Compliance that applies to all of the employees, officers and directors of
the Company and its subsidiaries. The purpose of our Code of Compliance is to provide written
standards that are reasonably designed to deter wrongdoing and to promote honest and ethical
conduct; full, fair, accurate, timely and understandable disclosure in reports and documents that
the Company files with the SEC and other public communications by the Company; compliance with
applicable governmental laws, rules and regulations; prompt internal reporting of violations of the
Code of Compliance; and accountability for adherence to the Code of Compliance. In 2007, we also
amended our Code of Compliance to include a formal policy regarding the approval of related party
transactions, which is to be administered by our Audit Committee. This policy is described more
fully below under Certain Relationships and Related Transactions. Each director, officer and
employee is required to read and certify that he or she has read, understands and will comply with
the Code of Compliance.
Under the Sarbanes-Oxley Act of 2002 and the SECs related rules, the Company is required to
disclose whether it has adopted a code of ethics that applies to the Companys principal executive
officer, principal financial officer, principal accounting officer or controller or persons
performing similar functions. The Nasdaq Stock Market LLC rules also require the Company to adopt
a code of conduct applicable to the Companys directors, officers and employees that meets the
SECs definition of code of ethics. Our Code of Compliance meets the SECs definition of code
of ethics. The Companys employees, including our Chief Executive Officer and senior financial
officers, are bound by our Code of Compliance.
A copy of our Code of Compliance can be obtained from the Investor Relations section of our
website at www.luminexcorp.com. We intend to disclose amendments to, or waivers from, the Code of
Compliance (to the extent applicable to our directors, Chief Executive Officer, principal financial
officer, principal accounting officer or persons performing similar functions) on our website.
Communications with Members of the Board
Our Board of Directors has established procedures for the Companys stockholders to
communicate with members of the Board of Directors. Stockholders may communicate with any of the
Companys directors, including the chairperson of any of the committees of the Board of Directors
or the presiding director, if any, by writing to a director, care of Corporate Secretary, Luminex
Corporation, 12212 Technology Boulevard, Austin, Texas 78727. Appropriate communications will be
forwarded to such director(s) by the Corporate Secretary.
Communications expressing concerns or complaints relating to accounting matters, internal
disclosure controls or controls over financial reporting, or auditing matters are handled in
accordance with procedures established by the Audit Committee, including, without limitation, a
dedicated hot line and email address. Under those procedures, concerns having to do with
accounting matters, internal disclosure controls or controls over financial reporting, or auditing
matters are presented by the Companys compliance officer to the Audit Committee
4
for consideration and, if appropriate, corrective action. The Companys compliance officer
maintains a log of correspondence addressed to directors and provides periodic summary reports
thereof for the Audit Committee.
Board Member Attendance at Annual Meeting of Stockholders
The Company strongly encourages each member of the Board of Directors to attend each annual
meeting of stockholders. Accordingly, we expect most, if not all, of the Companys directors to be
in attendance at the Meeting. All of our directors attended the 2006 annual meeting of
stockholders.
Meetings and Committees of the Board of Directors
The Board of Directors and its committees meet periodically during the year as deemed
appropriate. During 2006, the Board of Directors met six times. No director attended fewer than
75% of all the 2006 meetings of the Board of Directors and its committees on which he served.
The Board of Directors is generally responsible for establishing our broad corporate policies
and reviewing and assessing our corporate objectives and strategies, and other major transactions
and capital commitments. The Board of Directors currently has four standing committees: the Audit
Committee, the Compensation Committee, the Nominating and Corporate Governance Committee and the
Executive Committee. Each of our committees, other than the executive committee, operates under a
charter adopted by our Board of Directors. It is the policy of the Board and each committee to
periodically review its performance and the effectiveness of its charter and policies, as
applicable.
Audit Committee
The Audit Committee, which met nine times in 2006, currently consists of Mr. McNamara, who
serves as Chairman, Mr. Cresci and Mr. Thompson. The Board of Directors has determined that each
member of the Audit Committee meets the heightened independence requirements of the applicable
rules of the The Nasdaq Stock Market LLC and the SEC and has a basic understanding of finance and
accounting and is able to read and understand fundamental financial statements. The Board of
Directors has further determined that Mr. McNamara is an audit committee financial expert as such
term is defined in Item 407(d)(5)(ii) of Regulation S-K promulgated by the SEC. The Audit
Committees primary duties and responsibilities are to oversee the Companys accounting and
financial reporting processes and audits of the Companys financial statements; oversee the
integrity of the Companys systems of internal controls regarding finance, accounting and legal
compliance, including the oversight of the Companys internal audit function; oversee the
independence and performance of the Companys independent registered public accounting firm;
pre-approve all audit and permitted non-audit services to be performed by such firm; provide an
avenue of free and open communication among the independent registered public accountants,
management and the Board of Directors; and to approve related party transactions. It is the
function of the Audit Committee to help ensure the Companys financial statements accurately
reflect the Companys financial position and results of operations. In addition, the Audit
Committee, following its review of the audited financial statements, is charged with recommending
the audited financial statements to the Board of Directors for inclusion in the Companys annual
reports. Additional information regarding the purpose and functions of the Audit Committee is set
forth in the Report of the Audit Committee provided below.
Compensation Committee
The Compensation Committee, which met eight times in 2006, currently consists of Jay B.
Johnston, who serves as Chairman, Mr. Goad, Mr. Kever, and Mr. Vaillant. The Board of Directors
has determined that each member of the Compensation Committee is a non-employee director as
defined in Rule 16b-3 of the rules promulgated under the Securities Exchange Act of 1934, an
outside director for the purposes of the Internal Revenue Code of 1986, as amended (the Code),
and an independent director as defined by the applicable rules of The Nasdaq Stock Market LLC. The
Compensation Committees function is to establish and apply our compensation policies and
philosophies to assure that the executive officers, directors and other officers and key employees
are compensated in a manner consistent with the compensation policies and objectives adopted by the
Compensation Committee, competitive practice and the requirements of the appropriate regulatory
bodies. The Compensation Committee also administers our equity incentive plans. Additionally, the
Compensation Committee is charged with recommending the Compensation Discussion and Analysis to
the Board of Directors for inclusion
5
in the Companys Annual Report on Form 10-K. Additional information regarding the functions
performed by the Compensation Committee and the process undertaken by the Compensation Committee in
the determination of executive compensation is included under Executive and Director Compensation
Compensation Discussion and Analysis.
Nominating and Corporate Governance Committee
The Nominating and Corporate Governance Committee, which met two times in 2006, currently
consists of Mr. Cresci, who serves as Chairman, Mr. Thompson and Mr. Vaillant. The Board of
Directors has determined that each member of the Nominating and Corporate Governance Committee is
independent as defined by the applicable rules of the The Nasdaq Stock Market LLC. The Nominating
and Corporate Governance Committee provides assistance to the Board of Directors in identifying and
recommending individuals qualified to serve as directors of the Company, reviews the composition of
the Board of Directors, periodically evaluates the performance of the Board of Directors and its
committees, and reviews and recommends corporate governance policies for the Company. In addition,
the Nominating and Corporate Governance Committee recommends our various committee memberships
based upon, among other considerations, a directors available time commitment, background and/or
skill set it deems appropriate to adequately perform the responsibilities of the applicable
committee.
Executive Committee
The Executive Committee, which met four times in 2006, currently consists of Mr. Erickson, who
serves as Chairman, Mr. Balthrop and Mr. Loewenbaum. The Executive Committees function is to act
on behalf of the Board of Directors as a whole, to the extent delegated to the committee and
otherwise permitted by law.
Executive Sessions of Non-employee Directors
Generally, an executive session of non-employee directors is held in conjunction with each
regularly scheduled Board meeting and other times as deemed appropriate. The executive sessions
are generally led by Mr. Loewenbaum or the presiding director. At least two meetings per year
are also held by solely our independent directors, led by the presiding director. The presiding
director is the then chair of the Nominating and Corporate Governance Committee (currently Mr.
Cresci), as further described in our corporate governance guidelines.
Scientific Advisory Board
The Scientific Advisory Board (the Advisory Board), which met three times in 2006, was
created in 2005 to, among other responsibilities, provide strategic advice regarding the Companys
research and development efforts and to evaluate and provide new scientific and technological
perspectives relating to the current and future application of the Companys technologies. Our
former director, Dr. C. Thomas Caskey, was the initial member of the Advisory Board, which now also
includes Dr. Ronald Bowsher, Dr. Andrea Ferreira-Gonzalez, Dr. Thomas Joos and Dr. Gary Procop.
Dr. James Jacobson, Dr. John C. Carrano and Richard Janeczko also serve on the Advisory Board as
management representatives. It is expected that each member of our Advisory Board will be
qualified and experienced in the markets and/or industries in which our products are or may be
utilized and, with the exception of Dr. Jacobson and Dr. Carrano, are neither employees nor
directors of our Company. Additionally, the Company may invite members of our Board of Directors
to serve on the Advisory Board in their capacity as members of our Board of Directors in order to
help oversee and direct the Advisory Board and help communicate the Advisory Boards conclusions
and recommendations to our Board of Directors. The Advisory Board operates at the discretion of
the Board of Directors.
Compensation Committee Interlocks and Insider Participation
During 2006, the Compensation Committee of the Board of Directors consisted of Mr. Goad, who
served as Chairman, Mr. Kever and Mr. Vaillant, none of whom has ever been an officer or employee
of the Company or its subsidiaries. No interlocking relationship existed during 2006 between any
officer, member of our Board of Directors or the Compensation Committee and any officer, member of
the Board of Directors or compensation committee of any other company.
6
PROPOSAL 1 ELECTION OF CLASS I DIRECTORS
The number of directors on our Board of Directors is currently fixed at ten. Our certificate
of incorporation divides our Board of Directors into three classes which serve staggered three-year
terms. The terms of the Class I, Class II and Class III directors will expire upon the election
and qualification of directors at the annual meeting of stockholders to be held in 2007, 2008 and
2009, respectively.
Currently, our Board of Directors is composed of three Class I directors (consisting of Robert
J. Cresci, Thomas W. Erickson and Gerard Vaillant), three Class II directors (consisting of Fred C.
Goad, Jr., Jim D. Kever and Jay B. Johnston) and four Class III directors (consisting of Patrick J.
Balthrop, Sr., G. Walter Loewenbaum II, J. Stark Thompson, and Kevin M. McNamara).
At the Meeting, the stockholders will elect three Class I directors. Each of these directors
is to serve a three-year term until the 2010 annual meeting of stockholders and until a successor
is elected and qualified or until the directors earlier resignation or removal. The Board of
Directors and its Nominating and Corporate Governance Committee, pursuant to and consistent with
the nomination procedures described above under Corporate Governance, have nominated Messrs.
Cresci, Erickson and Vaillant for re-election as Class I directors. It is the intention of the
persons named in the proxy to vote the proxies for the election of the aforementioned nominees.
Proxies may not be voted for persons other than those, or for more persons than, named in the
proxy. If any nominee should be unwilling or become unavailable to serve as a director for any
reason, the persons named as proxies reserve full discretion to vote for such other person or
persons as may be properly nominated. The Board of Directors has no reason to believe that any of
the nominees will be unable or unwilling to serve as a director if elected.
Certain information about the Class I nominees for the Board of Directors, and those directors
whose terms do not expire at the Meeting, is furnished below.
Class I Director Nominees
Robert J. Cresci, age 63. Mr. Cresci has served as a member of the Board of Directors since
December 1996. He has been a Managing Director of Pecks Management Partners Ltd., an investment
management firm, since September 1990. Mr. Cresci currently serves on the Boards of Directors of
Sepracor Inc., j2 Global Communications, Inc., ContinuCare Corporation, SeraCare Life Sciences,
Inc. and several private companies. Mr. Cresci received his undergraduate degree from the United
States Military Academy at West Point and received his M.B.A. in Finance from the Columbia
University Graduate School of Business.
Thomas W. Erickson, age 56. Mr. Erickson has served as a member of the Board of Directors
since May 2004. Mr. Erickson served as the companys Interim President and Chief Executive Officer
from September 2002 until our hiring of Mr. Balthrop in May 2004. He is currently Chairman of the
Board of National Medical Health Card Systems, Inc. and PATHCare, Inc., and is a Senior Advisor to
New Mountain Capital, LLC, a private equity firm. Previously, he served as Chairman of the Board of
TransHealthcare, Inc., Chairman and Interim President and CEO of LifeCare Holdings, Inc., an
operator of long-term acute care hospitals, and Interim President and CEO of Omega Healthcare
Investors, Inc., a healthcare focused real estate investment trust. Mr. Erickson was also
co-founder, President and CEO of CareSelect Group, Inc., a physician practice management company.
Earlier in his career, he held several management positions at American Hospital Supply
Corporation. Mr. Erickson holds a Bachelors degree from University of Iowa and an M.B.A. from
Southern Methodist University.
Gerard Vaillant, age 65. Mr. Vaillant has served as a member of the Board of Directors since
February 2005. Mr. Vaillant held a number of positions within Johnson & Johnson from 1981 through
2004. Most recently, Mr. Vaillant served as Company Group Chairman until he retired. He also
served as Chairman for Ortho-Clinical Diagnostics, Inc., Veridex LLC and Therakos, Inc., and as a
member of several other operating committees within Johnson & Johnson during that period. In
addition, from 1992-1995, he was the Worldwide President of LifeScan, a company dedicated to
improving the quality of life for people with diabetes by developing, manufacturing and marketing a
wide range of blood glucose monitoring systems and software. He currently serves on the Board of
Directors of Sensors for Medicine and Science, Inc. and Tecan AG. He holds a Masters Degree &
Superior Certificate in Biochemistry & Industrial Chemistry from Paris University of Sciences and a
Degree in Marketing from Ecole Superieure de Commerce de Paris.
7
Class II Directors (Terms Expire in 2008)
Fred C. Goad, Jr., age 66. Mr. Goad has served as a member of the Board of Directors since
September 1997. Since August 2001, he has been a member in Voyent Partners, L.L.C., a private
investment company. Mr. Goad served as Co-Chief Executive Officer of the transaction services
division of WebMD Corporation (WebMD), a provider of healthcare transaction, information and
technology services, from June 2000 through March 2001. From March 1999 through May 2000, Mr. Goad
served as Senior Advisor to the Office of the President of the transaction services division of
Quintiles Transnational Corporation (Quintiles). Mr. Goad served as Co-Chief Executive Officer
and Chairman of Envoy Corporation (Envoy), a provider of electronic transaction processing
services for the healthcare industry, from June 1996 until Envoy was acquired by Quintiles in March
1999. From 1985 to June 1996, Mr. Goad served as President and Chief Executive Officer of Envoy.
Mr. Goad also serves on the Boards of Directors of Performance Food Group Company, Emageon
Inc. and several private companies.
Jim D. Kever, age 54. Mr. Kever has served as a member of the Board of Directors since
December 1996. He has been a member in Voyent Partners, L.L.C. since August 2001. Mr. Kever
served as Co-Chief Executive Officer of the transaction services division of WebMD from June 2000
to March 2001. From March 1999 through May 2000, Mr. Kever served as Chief Executive Officer of
the transaction services division of Quintiles. From August 1995 through March 1999, Mr. Kever was
the President and Co-Chief Executive Officer of Envoy. Mr. Kever joined Envoy as Treasurer and
General Counsel in October 1981. Mr. Kever serves on the Boards of Directors of 3D Systems
Corporation, Transaction Systems Architects, Inc. and Tyson Foods, Inc. Mr. Kever received a B.S.
in business and administration from the University of Arkansas in 1974 and a J.D. from the
Vanderbilt University School of Law in 1977.
Jay B. Johnston, age 64. Mr. Johnston has served as a member of the Board of Directors since
February 2005. Mr. Johnston currently serves as Chairman of QuesTek Innovations, LLC, a
privately-held company that designs and markets high tech materials. From 1975-1999, he held
numerous positions at Abbott Laboratories, most recently Corporate Vice President for Diagnostic
Assays and Systems. He held numerous other positions with Abbott Laboratories, including President
of Dainabot Co. Ltd. and Vice President Asia Pacific. Mr. Johnston has experience in general
management, product development, technology management, strategic marketing and business
development. He holds an M.B.A. in General Management from the Amos Tuck School of Business
Administration and a B.A. degree in Public Administration from Dartmouth College.
Class III Directors (Terms expire in 2009)
Patrick J. Balthrop, Sr., age 50. Mr. Balthrop has served as our President and Chief
Executive Officer since May 2004 and has served as a member of the Board of Directors and the
Executive Committee since September 2004. Prior to joining us, he was employed by Fisher
Scientific International Inc. where, since 2002, he served as President of Fisher Healthcare, a
Fisher Scientific company that focuses on diagnostic testing needs in the healthcare industry.
Prior to Fisher Scientific International, Mr. Balthrop served in a number of leadership positions
for over 20 years with Abbott Laboratories, primarily in Abbotts Diagnostics Division. Mr.
Balthrops most recent positions at Abbott were as head of worldwide commercial diagnostics
operations and as head of Abbott Vascular. His experience at Abbott and Fischer included sales,
marketing, manufacturing operations, international experience, research and development and senior
management. Mr. Balthrop holds an M.B.A. from the Kellogg Graduate School of Management of
Northwestern University, and a B.S. in Biology from Spring Hill College.
G. Walter Loewenbaum II, age 62. Mr. Loewenbaum has served as a member of the Board of
Directors since May 1995 and as Chairman of the Board of Directors since September 2002. He served
as Vice Chairman of the Board of Directors from April 1998 until January 2000. Mr. Loewenbaum
currently serves as Chairman and Chief Executive Officer of Finetooth
Corp, a provider of contract
management solutions. Additionally, from July 1999 through 2003, he served as a Member of LeCorgne
Loewenbaum & Co., LLC, an investment banking firm. From April 1990 until June 1999, he served as
the President, Chairman and Chief Executive Officer of Loewenbaum & Company, Inc. (f/k/a Southcoast
Capital), an investment banking company. Mr. Loewenbaum also has served as Chairman of the
Board of Directors of 3D Systems Corporation since September 1999, and was previously Chairman of
the Board of Directors of Envoy. He received a B.A. from the University of North Carolina.
8
Kevin M. McNamara, age 51. Mr. McNamara has served as a member of the Board of Directors
since May 2003. In addition, he provided financial and strategic consulting services to the
Company from October 2001 through December 2002. Mr. McNamara has served as Executive Vice
President and Chief Financial Officer of HealthSpring, Inc., a managed care company focused on
Medicare Advantage, since April 2005. Mr. McNamara also served as non-executive chairman from
April 2005 through January 2006 of MedAvant Healthcare Solutions (f/k/a ProxyMed, Inc.), a provider
of automated healthcare business and cost containment solutions for financial, administrative and
clinical transactions in the healthcare payments marketplace, and served as Interim Chief Executive
Officer of ProxyMed, Inc. from December 2004 through June 2005. Mr. McNamara previously served as
Chief Financial Officer of HCCA International, Inc., a healthcare management and recruitment
company from October 2002 to April 2005. From November 1999 until February 2001, Mr. McNamara
served as Chief Executive Officer and a director of Private Business, Inc., a provider of
electronic commerce solutions that help community banks provide accounts receivable financing to
their small business customers. From 1996 to 1999, Mr. McNamara served as Senior Vice President
and Chief Financial Officer of Envoy. Mr. McNamara is a Certified Public Accountant (inactive) and
holds a B.S. in Accounting from Virginia Commonwealth University and a M.B.A. from the University
of Richmond.
J. Stark Thompson, age 65. Mr. Thompson has served as a member of the Board of Directors
since June 2005. Mr. Thompson has served as Non-Executive Chairman of the Board of Directors of
Gene Logic, Inc. since November 2004 and as a director since February 2002. Mr. Thompson is the
sole proprietor of Black Horse Yachts, LLC, a manufacturer of semi-custom yachts. Mr. Thompson
most recently served as President, Chief Executive Officer and Director of Life Technologies, Inc.,
a developer, manufacturer and supplier of products and services for life science researchers and
biotechnology companies, from 1988 until his retirement in 2000. He previously held a number of
research, sales, product development, operations and other positions over a 21 year career with the
E. I. Du Pont deNemours and Company. He also serves on the board of various private and civic
organizations. Mr. Thompson has a Bachelor of Science degree from Muskingum College and a Masters
of Science and Ph.D. in Physiological Chemistry from the Ohio State University.
Required Vote; Recommendation of the Board
Election of Class I directors will be determined by a plurality of the votes cast at the
Meeting.
The Board of Directors unanimously recommends that stockholders vote FOR the election of its
nominees for Class I directors.
PROPOSAL 2 RATIFICATION OF APPOINTMENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee has appointed Ernst & Young LLP as the Companys independent registered
public accounting firm to audit the financial statements of the Company and to perform other
accounting services, if appropriate, for the year ending December 31, 2007. Such appointment will
be presented to the stockholders for ratification at the Meeting. A representative of Ernst &
Young LLP is expected to be present at the Meeting to respond to questions from stockholders and
will be given the opportunity to make a statement if so desired.
Stockholder ratification of the selection of Ernst & Young LLP as the Companys independent
registered public accountants is not required by the Companys bylaws or otherwise. However, the
Audit Committee is submitting the selection of Ernst & Young LLP to the stockholders for
ratification. If the stockholders fail to ratify the selection, the Audit Committee will
reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit
Committee in its discretion may direct the appointment of a different independent registered public
accounting firm at any time during the year if it determines that such a change would be in the
best interests of the Company and its stockholders.
Fees paid to Ernst & Young LLP for services provided during the years ended December 31, 2006
and 2005 are presented below.
Audit Fees. The aggregate audit fees billed to us by Ernst & Young LLP for professional
services rendered for the audit of our annual consolidated financial statements, for the reviews of
the consolidated financial statements
9
included in our quarterly reports on Form 10-Q, for the audit of managements report on the
effectiveness of our internal control over financial reporting, as required under Section 404 of
the Sarbanes-Oxley Act of 2002, and other services that are normally provided by the independent
auditor in connection with statutory and regulatory filings totaled $323,500 for 2006 and $280,000
for 2005.
Audit-Related Fees. There were no other fees billed to us by Ernst & Young LLP for assurance
and related services with regard to the performance of the audit or review of the Companys
consolidated financial statements, and for the review of the Companys internal controls over
financial reporting and not described above under Audit Fees, for 2006 and 2005.
Tax Fees. The aggregate fees billed by Ernst & Young LLP for professional services rendered
for tax return preparation were $10,000 in 2006 and $42,000 for 2005.
All Other Fees. There were no fees billed by Ernst & Young LLP for products or services other
than those described above for 2006 and 2005.
The Restated Audit Committee Charter, among other things, requires the Audit Committee to
pre-approve all audit and permitted non-audit services (including the fees and terms thereof) to be
performed for the Company by its independent auditor. The Audit Committee has adopted a
pre-approval policy in order to ensure that the performance of audit and non-audit services by the
independent auditor does not impair the auditors independence. The policy provides for the
general pre-approval of specific types of services, gives guidance to management as to the specific
type of services that are eligible for pre-approval and provides cost limits for each such service
on an annual basis. The policy requires specific pre-approval of all other permitted services.
Requests or applications to provide services that require separate approval by the Audit Committee
are submitted by the Companys Chief Financial Officer to the Audit Committee and must include a
statement as to whether, in the Chief Financial Officers view, the request or application is
consistent with the SECs rules on auditor independence. The Audit Committee may delegate
pre-approval authority to one or more of its members who shall report any pre-approval decisions to
the Audit Committee at its next scheduled meeting.
All audit related services, tax services and other services provided in 2006 and 2005 were
pre-approved by the Audit Committee. The Audit Committee concluded that the provision of such
services by Ernst & Young LLP was compatible with the maintenance of the firms independence in the
conduct of its auditing functions.
Required Vote; Recommendation of the Board
Approval of this proposal requires the affirmative vote of a majority of the shares present in
person or by proxy and entitled to vote on the matter.
The Board of Directors unanimously recommends that stockholders vote FOR Proposal 2.
10
REPORT OF THE AUDIT COMMITTEE
The following Report of the Audit Committee does not constitute soliciting material and should
not be deemed filed or incorporated by reference into any other Company filing under the Securities
Act of 1933 or the Securities Exchange Act of 1934, except to the extent the Company specifically
incorporates this Report by reference therein.
To the Stockholders of Luminex Corporation:
The Board of Directors maintains an Audit Committee comprised of three independent directors.
The Board of Directors and the Audit Committee believe that the Audit Committees current member
composition satisfies the rules of The Nasdaq Stock Market LLC that govern audit committee
composition, including the requirement that audit committee members meet the heightened
independence requirements as contemplated by the applicable rules of the The Nasdaq Stock Market
LLC. The Audit Committee operates under a written charter, which was adopted by the Board of
Directors (as amended to date, the Restated Audit Committee Charter). A copy of the Restated
Audit Committee Charter may be viewed on the Investor Relations section of our website at
www.luminexcorp.com.
Pursuant to the Restated Audit Committee Charter, the Audit Committee oversees the financial
reporting process on behalf of the entire Board of Directors. The Audit Committee is responsible
for the appointment, compensation and oversight of the work of the Companys independent registered
public accountants. Management has the primary responsibility for the financial statements and the
reporting process including the systems of internal controls. Our independent registered public
accountants are responsible for performing an independent audit of the Companys financial
statements in accordance with standards established by the Public Company Accounting Oversight
Board, expressing an opinion on the conformity of our audited financial statements to generally
accepted accounting principles and auditing managements assessment of the effectiveness of
internal control over financial reporting and issuing a report thereon. In fulfilling its
oversight responsibilities, the Audit Committee reviews and discusses with management and the
independent registered public accountants the audited and interim financial statements included in
our reports filed with the SEC in advance of the filings of such reports.
The Audit Committee has reviewed and discussed the audited financial statements with
management and the independent registered public accountants. Furthermore, the Audit Committee has
reviewed and discussed with the independent registered public accountants all communications
required by generally accepted auditing standards, including those described in Statement on
Auditing Standards No. 61 (Communication with Audit Committees), as amended by Statement on
Auditing Standards No. 90 (Audit Committee Communications). The Audit Committee has also received
from the independent registered public accountants the written disclosures required by Independence
Standards Board Standard No. 1 (Independence Discussions with Audit Committees) and has discussed
with them their independence from the Company and its management.
The Audit Committee discussed with the independent registered public accountants the overall
scope and plans for their audit. The Audit Committee met with the independent registered public
accountants, with and without management present, to discuss the results of their examination,
their evaluation of the Companys internal controls requirements under Section 404 of the
Sarbanes-Oxley Act of 2002, and the overall quality of the Companys financial reporting.
In reliance on the reviews and discussions referred to above, the Audit Committee recommended
to the Board of Directors (and the Board of Directors approved) that the audited financial
statements be included in our Annual Report on Form 10-K for the year ended December 31, 2006, as
filed with the SEC.
SUBMITTED BY THE AUDIT COMMITTEE OF
THE BOARD OF DIRECTORS
Kevin M. McNamara (Chairman)
Robert J. Cresci
J. Stark Thompson
11
EXECUTIVE AND DIRECTOR COMPENSATION
Compensation Discussion And Analysis
Overview of Compensation Process. The Compensation Committee of the Board of Directors (the
Committee) is responsible for establishing the compensation programs for the Companys Chief
Executive Officer (the CEO) and other executive officers. In addition, the Committee reviews and
makes recommendations to the full board regarding non-employee director compensation. The
Committee administers the Companys 2006 Equity Incentive Plan (the Equity Plan) under which
option and restricted share grants, restricted share units and other awards may be made to key
employees, directors and consultants, together with the Luminex Corporation 2006 Management Stock
Purchase Plan (the MSPP) and certain historical equity plans under which awards remain
outstanding but no further grants may be made. Additional information regarding the functions
performed by the Committee is included above under Corporate GovernanceMeetings and Committees of
the Board of DirectorsCompensation Committee.
The Committee annually reviews executive compensation and the Companys compensation policies
in an attempt to ensure that the CEO and the other executive officers are rewarded appropriately
for their contributions to the Company and that the overall compensation strategy supports the
objectives of our organization, as well as stockholder interests. The Committee will review
tally sheets quantifying every aspect, current or contingent, of executive compensation as part
of its annual compensation review. The Committee intends to seek the advice and analyses of
compensation consultants as and when it deems appropriate in reviewing our compensation strategies
and policies. Input from senior executives may also, and generally will, be requested to assist
our compensation consultants in understanding our organization and business objectives and
challenges, as well as customizing any competitive market surveys we may request. In addition,
given the CEOs insight into internal pay equity and positioning issues as well as executive
performance, skill sets, potential and past and projected responsibilities, the views and
recommendations of the CEO are solicited by the Committee with respect to executive compensation as
part of the annual review process. These recommendations are considered by the Committee as an
additional factor in the final compensation decisions and are generally given significant weight
provided such recommendations are otherwise consistent with the Committees compensation objectives
and strategies. The Committee on occasion will also solicit the views of other board members with
particular insight into relevant matters, who may, upon request, attend Committee meetings in an
observer capacity. However, the Committee makes all final decisions regarding named executive
compensation in meetings without management present. Moreover, the Committee retains exclusive
authority over the hiring of its compensation consultants and executive compensation decisions.
The Committee does not delegate the authority to make equity or other compensatory awards to any
officer or other employee.
Compensation Objectives. The Committee has established the following primary objectives in
designing and reviewing compensation for our CEO and other executive officers:
|
|
|
Attract, reward and retain skilled employees in a competitive recruiting
environment; |
|
|
|
|
Provide annual incentives for executives to achieve designated quantitative and
qualitative measures of performance; |
|
|
|
|
Reward corporate growth and encourage measured risk-taking in support of our
corporate objectives; and |
|
|
|
|
Align the interests of our executives with those of our stockholders by creating
long-term incentives that deliver value based on long-term performance and stock price
appreciation. |
Compensation Philosophy. The Committee anticipates the Company will have significant future
growth, in terms of both revenue and the expansion and complexity of our operations. Therefore,
our compensation policies must primarily be designed to attract and retain the required talent to
support our anticipated growth. Simultaneously, our policies should foster the growth and
development of our executive team. The Committee also intends that each element of our
compensation program be designed to simultaneously fulfill one or more of our compensation
objectives described above. With respect to our objective of aligning executive behavior with
stockholder interests, the Committee is committed to a strong, positive link between our financial
and strategic performance and our compensation and benefits practices. The Committee believes the
primary way to solidify this link is to have a substantial portion of each officers compensation
contingent upon performance as a company, as well as upon his or her individual performance.
Accordingly, in addition to the Companys strategic and financial
12
performance, the Committees compensation philosophy for an executive officer allows for
flexibility in assessing an overall analysis of the executives performance for the prior year,
projected role and responsibilities, required impact on execution of Company strategy, external pay
practices and competitive market conditions, total cash compensation and relative equity
positioning internally, recommendations from our CEO and any compensation consultants it may
engage, and other factors the Committee deems appropriate. Our philosophy also considers an
officers prior experience and professional status, employee retention, vulnerability to
recruitment by other companies and the difficulty and costs associated with replacing executive
talent. Accordingly, we do not believe in a one size fits all compensation policy and the
Committee strives to make individual compensation decisions that reward performance while
appropriately reflecting the unique attributes of our Company, particularly our stage of
development, evolving business plan and diverse operational focus (including research, medical
device, diagnostic and administrative focuses), and each employee. However, for our most senior
executives, including our CEO, our philosophy strongly favors performance-based incentives that are
consistent with stockholder interests.
Program Design.
Primary Elements and Compensation Mix. Based on the aforementioned objectives and
philosophies, the Committee has designed our executives compensation packages around three primary
elements:
|
|
|
base salary; |
|
|
|
|
annual variable performance awards payable in cash; and |
|
|
|
|
long-term stock-based incentive awards. |
While we do not support rigid adherence to compensatory formulas, there are general pay
positioning policies, or benchmarks, we refer to which have been derived consistent with our
general compensation objectives and philosophies. Our benchmark for base salary is to be
competitive with median (50th percentile) salary levels in an appropriate peer group
based, to the extent possible, upon comparable positions. Recognizing that we compete with larger
companies for executive talent, the Committees desire is to provide total short-term cash
opportunities near the peer group median (50th percentile) for meeting targeted annual
goals, but allow for upside for meeting or exceeding performance goals established by the
Committee. The Committees ultimate goal is to position total potential compensation opportunities
with a target upside at the 75th percentile of our peer group, provided the Company
delivers superior performance.
To ensure executives are being compensated fairly, and otherwise generally consistent with our
pay positioning policies, the Committee collects compensation data from our peer group. However,
these survey results will be used by the Committee solely as a baseline reference for consideration
in the context of our compensation objectives and philosophies described above. Therefore, certain
executives may be compensated below or above the Committees benchmarks (including target mix as
described below) based on subjective factors consistent with our flexible compensation philosophy
and otherwise as deemed necessary to accomplish our compensation objectives.
With respect to compensation mix, we generally believe 55% to 75%, typically increasing with
level of responsibility, of an executives total compensation opportunity should be performance and
equity based, with the equity component approximating 50% of target total compensation
opportunities at the CEO level, and ranging from approximately 30% to 45% for the other named
executive officers. We believe emphasis on equity focuses our executives on long-term performance.
Additionally, we generally believe 15% to 30% of an executives total compensation opportunities,
typically increasing with level of responsibility, should be allocated to short-term performance
bonus opportunities. This reflects our desire to reward and encourage the achievement of short-term
business objectives and performance which should also inure to the benefit of our stockholders.
The following provides additional detail regarding the Companys three primary compensation
elements:
Base Salary. Base compensation for our executive officers has historically been
established by the terms of employment agreements between the Company and the executives or, with
respect to promotions, is established by the Committee in conjunction with the CEO. The
Committees goal is to generally maintain base salaries near the 50th percentile of our
peer group. We believe our benchmark with respect to base salary is necessary to be competitive in
our recruitment and retention efforts. Notwithstanding our use of benchmarks, the
13
Committee will subjectively determine appropriate levels of base compensation for executive
officers based upon various factors consistent with our compensation objectives and philosophies.
Short-Term Performance Bonus Opportunity. The Committee believes that a significant
portion of compensation should be linked to Company operating performance and individual
contributions. To achieve this link with regard to short-term performance, the Committee will
primarily rely on cash-based bonuses awarded to executive officers that are targeted as a
percentage of base salary based on specific performance goals, including financial and personal,
determined near the beginning of each fiscal year. Our CEO typically recommends performance goals
to the Committee, which are then reviewed and approved or modified in the Committees discretion.
The minimum bonus opportunities are generally as set forth in the executives employment agreement,
subject to increase at the Committees discretion. We do not intend to publicly disclose the
specific Company performance targets to the extent they reflect competitive, sensitive information.
However, we intend to approve target performance goals that are both attainable and practical
based on a realistic estimate of our financial performance for the coming year, with maximum
payouts tied to superior performance goals and no payouts for performance below a minimum threshold
level. In our view, this bonus program provides a bonus incentive firmly aligned with stockholder
interests. It is also our general goal to maintain consistency from year to year in the level of
difficulty in achieving the various financial performance thresholds. However, as the many
variables that ultimately determine our performance outcomes are subject to numerous risks and
uncertainties, our actual performance, and corresponding payouts under our bonus plans, may be
subject to a wide range of outcomes.
We believe it is important to incorporate individual goals into our performance incentive
program because financial performance on the Company level is not necessarily indicative of the
total value an executive may contribute to the Company. While certain individual goals can be
measured objectively, others, such as leadership and teamwork, involve subjective assessment that
will ultimately be left to the Committee, based primarily on recommendations of our CEO.
Additionally, where an executives primary responsibility may be in a particular business unit or
function (for example, marketing or the Luminex Bioscience Group), the performance goals may be
more heavily weighted towards specific financial or other achievements in that unit or function.
Long-Term Stock-Based Incentive Compensation. We believe that stock options and
restricted share awards, the primary components of our long-term stock-based incentive program,
have been effective in aligning the interests of our executive team with those of our stockholders.
The availability of stock ownership has allowed us to attract and retain talented executives that
are interested in building and growing our Company. We also believe that stock ownership has
helped to create a culture that encourages our executives to think and act as stockholders. To
further this alignment of interests with our stockholders, we have adopted stock ownership and
retention guidelines that are further described below.
Historically, the Committee utilized stock options as long-term incentives; however, in 2005
and 2006, all long-term equity awards were in the form of restricted shares, primarily to allow us
to use fewer shares than pursuant to traditional option grants. In 2007, the Committee, with the
assistance of its consultant, analyzed our utilization of restricted shares as the sole equity
award vehicle and has determined to utilize a combination of restricted shares (subject to five
year vesting) and stock options (subject to three year vesting). This modification was made
primarily to remain competitive with the practices of our peer group who generally rely on stock
options as a significant component of equity compensation. We believe our use of restricted
shares, in addition to limiting dilution, serves our compensation objectives of retention and
alignment interests with our stockholders given the five year vesting. At the same time, the use
of stock options, in addition to contributing to the competitiveness of our compensation packages,
further motivates the executives to improve stockholder value over an extended time horizon. The
Committee believes its policy to utilize a combination of restricted shares and options provides it
the flexibility to set what it believe to be optimal combinations of retention- and
performance-focused equity incentives.
In conjunction with 2007 equity awards, the Committee determined the desired value to be
delivered to an executive pursuant to the equity component of his or her total compensation
opportunity, and allocated 75% of that value to restricted shares and 25% to stock options. The
number of restricted shares granted are generally determined by dividing the dollar amount
allocated to the restricted share component by the fair market value of the shares on the date of
grant. The Committee did not apply a discount to the value of these shares to reflect the
forfeiture restrictions associated with service-based vesting. The number of shares subject to
options granted are generally determined by dividing the dollar amount allocated to the option
component by the value of an option share with reference to the fair market value of the shares on
the date of grant calculated pursuant to a modified
14
Black-Scholes model specific to the Company. For 2007, this calculation resulted in a option
share value of approximately 50% of the fair market value of our common stock on the grant date.
The Committee may also utilize restricted share units, settled in stock upon vesting, in lieu of
restricted shares where deemed appropriate in certain circumstances, such as the personal tax
impact of granting restricted shares to our Canadian employees acquired in connection with the
Companys acquisition of Tm Bioscience in March 2007.
Except with respect to new hires or promotions, we generally make annual equity compensation
awards each year no earlier than the meeting in which we approve the prior years annual
performance bonuses. This allows us to assess the prior years total compensation when considering
current year grants. The Committees meeting schedule is typically determined several weeks or
months in advance, and the historical proximity of any awards to earnings announcements or other
market events was coincidental. Based on a review of the Companys historical equity grants at the
request of the Audit Committee, the Companys internal auditors reported that they did not find any
material accounting or timing issues associated with such grants. While it is our goal to grant
equity incentives during trading windows under our insider trading policy and while senior
management is not in possession of material non-public information or in close proximity to a
pending financial earnings release, there are occasions where this is not practicable. In these
cases, the Committee will consider whether to adjust the number of shares and/or shares subject to
an option grant in the event we believe the subsequent announcement of such material non-public
information or financial earnings would positively impact our stock price to avoid the appearance
of spring-loading or a windfall at the Companys expense.
The restricted shares are generally subject to time vesting over five years in equal annual
increments on the anniversary date of such grants, while 2007 stock option grants will vest over
three years in equal annual increments. Except with respect to Mr. Balthrop (as described below),
we have not utilized performance-based vesting restrictions with respect to equity awards. While we
have considered the merits of performance-based vesting, we believe time-based equity awards
appropriately align the interests of our executives with those of our stockholders. Time-based
vesting of restricted shares and stock options provide economic benefit only to the extent the
employee maintains a long-term business relationship with and commitment to the Company. Stock
price appreciation is required in order to realize value from stock options, and is required to
create significant additional value with respect to restricted shares. Setting appropriate
performance goals with respect to equity vesting has also been challenging with a company with a
limited history of profitability and consistency with respect to key financial metrics. However,
the Committee believes that performance-based vesting criteria may become viable as the Company
matures and forecasting of performance parameters over a several year time horizon becomes more
predictable.
Our employment agreements with our named executive officers provide for acceleration of
vesting, or lapse of restrictions, in connection with a change in control. We believed such
single-trigger acceleration provisions to be consistent with market practice for executives at
the time each executives employment agreement was negotiated. We felt that no accelerated vesting
provision may put us at a competitive disadvantage in our recruiting and retention efforts, as
employees often consider equity upside opportunities in a change in control transaction a critical
element of compensation. Additionally, the absence of an accelerated vesting provision provides no
security that equity related consideration will be earned in the event the Company is sold or the
subject of a hostile takeover and could impact and an employees willingness to work through a
merger transaction which could be beneficial to our stockholders. The outstanding restricted
shares and stock options of our named executive officers also vest in full upon their death or
disability.
Executive Compensation for 2006. For 2006, the Committee caused the Company to engage
Compensation Resources, Inc. (CRI) to assist it in reviewing the existing executive compensation
strategies and policies and, in particular, performing detailed peer and market analyses as well as
internal pay equity and positioning analyses. CRI was selected, in part, because of its national
recognition as a compensation consulting firm. The focus was a market study of total overall
executive compensation for the executive officers with an emphasis on base salary,
performance-based cash incentives and long-term equity compensation. The Committee also advised
CRI of its compensation objectives and philosophies in order to specifically tailor the survey.
Peer companies were selected, with the concurrence of the Committee, from within the biotechnology
(including research, medical device and diagnostic) industries and a group of larger companies
targeted by the Committee that were believed to be relevant peers. The biotechnology company peers
were selected primarily based on market capitalization and/or revenue (within a range of
approximately one-half to double the Companys market capitalization and/or revenue), as well as
similar organizational and operational complexity and stage of development. The study focused
primarily on public
15
companies due to the lack of reliable data with respect to potentially similar private companies.
The following peer companies were included in the analysis:
|
|
|
|
|
Accelrys, Inc.
|
|
Enzo Biochem Inc.
|
|
New Brunswick Scientific Co., Inc. |
Anesiva, Inc.
|
|
Infinity Pharmaceuticals, Inc.
|
|
Third Wave Technologies, Inc. |
(f/k/a Corgentech Inc.)
|
|
(f/k/a Discovery Partners International)
|
|
Transgenomic, Inc. |
ArQule Inc.
|
|
Illumina Inc
|
|
Tripos, Inc. |
Biosite, Inc.
|
|
Immunogen Inc.
|
|
Viacell, Inc. |
Caliper Life Sciences, Inc.
|
|
Lifecell Corp.
|
|
Xenogen Corporation |
Cepheid Inc.
|
|
Maxygen, Inc.
|
|
Zymogenetics, Inc |
Digene Corporation
|
|
Monogram Biosciences, Inc. |
|
|
The analysis reviewed the competitive pay practices, using publicly available 2005 proxy statement
data, of the peer companies. Published executive compensation surveys were also utilized, though
more weight was given to the proxy data. Specific executive position matches within the peer group
were based on the degree of compatibility of the positions roles and responsibilities. Certain
executive officers were consulted in order to establish appropriate position comparables and to
help CRI understand our business strategy and objectives.
The 2006 compensation of Patrick J. Balthrop, our CEO and President, Harriss T. Currie, our
Vice President, Finance and Chief Financial Officer and Treasurer, Randel S. Marfin, our Vice
President, Luminex Bioscience Group, James W. Jacobson, our Vice President, Research and
Development and David S. Reiter, our Vice President, General Counsel and Corporate Secretary
(together, the named executive officers) is listed below under the Summary Compensation Table.
Base Salary. The results of the market analysis performed by CRI revealed base
salaries of our named executive officers (overall) were slightly above the peer group marketplace.
As a result of the Committees evaluation, named executive officer base salaries did not increase
in 2006.
Performance-based Cash Awards. With respect to annual cash performance awards for the
named executive officers, the Committee approved 2006 performance award opportunities based upon
achievement of Company performance goals (Company Goals) as well as personal business objectives
(Individual Goals).
For 2006, for named executive officers other than the CEO, the total target awards under the
performance-based cash bonus plan were weighted 50% for the achievement of Company Goals and 50%
for the achievement of Individual Goals, and were based on a target bonus established by the
Committee for each participant. The weighting of specific components of the Company Goals and
Individual Goals varied for each executive taking into account, among other factors,
responsibilities, seniority and other strategic initiatives in which an executive may be involved.
The target bonuses ranged from 40% to 50% of each executives base salary (excluding the CEO)
depending on responsibility levels and the provisions in applicable employment contracts, and were
not increased for our named executive officers for 2006 as the market study performed by CRI
indicated these targets were general at or above the targeted ranges within our peer group. The
Company Goals were subject to an over/underachievement scale with possible payouts of 0% to 200% of
the potential bonus for Company Goals based on financial results in relation to the applicable
performance targets. Accordingly, significant underachievement is not rewarded in the design of
our plan. Individual Goals were not subject to an over/underachievement scale. Accordingly, total
awards could range from zero to a maximum of 150% of the target bonus.
The Company Goals were based on a number of specific financial metrics, including total
revenue, combined consumables and royalty revenue, and adjusted operating profits targets, as well
as achieving absolute profitability. The target performance goals were primarily determined by
reference to our business plan (including, in some cases, targets in excess of budget), thus
requiring aggregate overachievement in order to receive payouts in excess of 100% of the target
portion of the bonus related to Company Goals. The Individual Goals varied by executive and were
based on specified management initiatives and projects for 2006 and leadership and team
contributions, with each objective given a specified weight (typically 30-35% (out of the total
target award opportunity) for projects, and 15-20% for leadership and team contributions). The
project goals were graded 100% for on time completion, 75% for completed late, 50% for partially
complete and 0% for failure to produce even partial completion, in each case in the subjective
judgment of the Committee based, in part, upon the recommendation of the CEO.
16
In general, the Company Goals were achieved and/or exceeded in 2006 and Individual Goals were
modestly underachieved. Accordingly, total bonus payouts for our named executive officers (other
than the CEO) ranged from 95% to 125% (out of a maximum opportunity of 150%) of their target award
opportunities.
For 2006, the CEO performance-based cash bonus plan was based upon achievement of certain
financial targets, including operating performance targets and combined consumable and royalty
revenue on a Company level, as well as business objectives, in each case as determined by the
Committee. The business objectives were based on specified management initiatives, with each
objective given a specific weight. The total target awards under the CEO plan were weighted
approximately 50% for the achievement of the Company performance goals and approximately 50% for
the achievement of Mr. Balthrops business objectives. These target performance goals and
objectives were primarily determined with reference to our business plan (including, in some cases,
targets in excess of budget) and strategic goals and initiatives, thus requiring overachievement
in order to receive payouts equal to 100% of the target bonus. The individual objectives were
subject to the grading system described above with respect to the other executive officers. The
target bonus established by the Committee was 100% of Mr. Balthrops base salary, as set forth in
his employment agreement. Mr. Balthrops total award under the CEO bonus plan ranged from zero to
a maximum of 100% of the target bonus, with no payouts permitted for performance below the
respective target thresholds. Accordingly, Mr. Balthrops potential bonus was not subject to an
over/underachievement scale. The Committee determined Mr. Balthrop had achieved each of the
personal objectives required under his plan but that certain of the Company performance-based goals
were not achieved resulting in a bonus equal to 84% of his target bonus. Notwithstanding, the
Committee authorized an additional subjective bonus of $100,000 after consideration of factors it
deemed relevant, including its view that certain financial performance targets were based on overly
aggressive assumptions and the achievement of significant strategic objectives in 2006, including
the execution of the acquisition agreement for Tm Bioscience. Accordingly, Mr. Balthrop received
an aggregate cash performance bonus for 2006 of 109% of his target bonus.
By way of historical context, in 2004 and 2005 our executives achieved payouts under the bonus
plan at about 100% of target overall, with Company Goals generally overachieved, offset by failure
to fully achieve 100% of the Individual Goals.
Long-Term Stock-Based Incentive Compensation. The CRI market analysis revealed that
while the Company was generally paying the respective executive officers aggregate cash
compensation greater than the target 50th percentile, the Company was generally
underpaying with respect to total compensation opportunities targeted at the 75th
percentile, primarily as a result of under-compensating with respect to the equity component.
However, in light of the fact that the total cash compensation was slightly above the peer group
marketplace, target equity awards were not increased to the levels inherent in the component mix
suggested by the survey in certain cases to avoid exceeding the overall total target compensation
goals for such executives. Based on the foregoing, recommendations of the CEO, and other factors
deemed relevant, the Committee authorized the issuance of restricted share awards in 2006 to each
of the Companys executive officers (other than the CEO) ranging from 8,855 14,772 shares, as
further detailed in the Grant of Plan-Based Awards in 2006 table.
The benchmarking data reflected that Mr. Balthrop was significantly under compensated with
respect to equity incentive compensation. The Committee deemed it appropriate to grant Mr.
Balthrop 32,000 restricted shares in 2006. This grant was designed to reflect the importance of
the CEO position and to increase Mr. Balthrops total compensation as compared with 2005.
The restricted shares granted in 2006 are generally subject to time vesting over five years in
equal annual increments on the anniversary date of such grants. See above under Program
DesignLong-Term Stock-Based Incentive Compensation.
Executive Compensation for 2007. The Committee engaged Hewitt Associates LLC, or Hewitt, to
serve as the Committees compensation consultant for 2007. Hewitt was engaged to review our
existing executive compensation strategies and policies and to perform a detailed peer group
compensation analyses. Hewitt has also been requested to review, over the remainder of 2007, our
outside director compensation policies and to make recommendations regarding compensation policies
for our top 30 officers and eventually across our employee-base, including the development of
sustainable and appropriate future job development and market pricing strategies.
17
As a result of the Committees process for 2007, it was determined that our cash-based
compensation programs, including performance bonus opportunities, for our named executive officers
were generally appropriate and reasonable in light of our compensation philosophy, objectives and
benchmarks. Accordingly, these programs will be substantially the same in 2007 for our named
executive officers (other than our CEO), subject to modest increases in base salary (ranging from
2.5% to 5.5%, primarily to account for inflation adjustments and overall 2006 performance ratings
as recommended by our CEO). The Committee also made modifications to applicable performance
objectives and corresponding weighting under our cash-based bonus plans to reflect updates to
responsibilities and our business plan and strategic and other initiatives for 2007. However,
target bonus amounts, expressed as a percentage of base salary, for our named executive officers
did not change for 2007. Mr. Balthrops salary was increased 8%, reflecting the Committees view
of his superior performance in 2006 and his overall value to the Company. In addition, primarily
to more closely align his bonus structure with those of the other named executive officers, Mr.
Balthrops bonus plan was modified to include an overachievement feature allowing Mr. Balthrop to
earn up to 126.25% of his target bonus amount (100% of base salary) for overachievement of certain
of his plan objectives.
The targeted value of equity awards for our named executive officers was generally increased,
with the specific increase based on various factors reflecting the Committees application of our
flexible compensation philosophy. However, the most significant increase was with respect to Mr.
Balthrop, primarily in recognition of the Committees view as to his performance since his hiring
in May 2004, anticipated future contributions, and the Committees desire to be competitive within
our peer group for CEOs with comparable experience. The Committee believes the increased
performance based compensation opportunities will further motivate Mr. Balthrop to increase the
long-term value of the Company. Additionally, as described above, the Committee determined in 2007
to utilize a mix of restricted shares and stock options as the long-term equity compensation
vehicles.
The Committee also determined to amend Mr. Balthrops performance-vesting 200,000 restricted
share agreement to provide for cliff vesting of any unvested restricted shares at the end of the
five-year performance period under the initial grant to the extent any or all of the performance
measures have not been previously achieved. The initial terms of the restricted share award are
described further under footnote (4) to the Outstanding Equity Awards at 2006 Fiscal Year-End
Table. This determination was made following a comprehensive review of Mr. Balthrops
compensation since his arrival in May 2004. While it is currently unclear whether any or all of
the performance targets will be met within the five-year performance period, it was the Committees
desire for Mr. Balthrop to retain these shares at the end of the performance period regardless,
primarily in view of his total compensation since his arrival, the strength of his performance
during his tenure as observed by the Committee and Mr. Balthrops continuing role, and anticipated
contributions, as our CEO. The Committee also considered the accounting impact of this amendment,
as well as the difficulty in forecasting long-term performance goals for the Company at the time
the restricted shares were issued and the impact of the Tm Bioscience acquisition upon the
Companys financial performance, in deciding to approve the amendment.
Change in Control; Termination Benefits. We believe that reasonable and appropriate severance
and change in control benefits are necessary in order to be competitive in our executive recruiting
and retention efforts. These benefits are also the product of a generally competitive recruiting
environment within our industry and as a result of our location in Austin, Texas, which often
requires new executives to relocate from other states. We also believe that a change in control
arrangement will provide an executive security that will likely reduce the reluctance of an
executive to pursue a change in control transaction that could be in the best interests of our
stockholders. Finally, while we have not conducted a study to confirm this, we believe formalized
severance and change in control arrangements are common benefits offered by employers competing for
similar executive talent. While the Committee will receive this information as part of its review
of annual tallies of total executive compensation (including contingent compensation), we do not
typically consider the value of potential severance and change in control payments when assessing
annual compensation as these payouts are contingent and have a primary purpose unrelated to
ordinary compensation matters and objectives. The Committee generally assesses these potential
payouts only in view of their reasonableness during negotiations with a new hire, and periodically
in light of competitive market conditions.
In light of the foregoing, upon their joining the Company, we entered into employment
agreements with our named executive officers. These agreements generally provide for severance
payments (including premiums for certain continuing health and insurance benefits) where the
executive is terminated without cause (including the
18
Companys failure to renew the employment agreement) or, except with respect to Messrs. Marfin and
Jacobson, as a result of incapacity or death, or if the executive resigns for good reason.
Additionally, certain enhanced severance for Messrs. Marfin and Jacobson may apply in the event the
termination or resignation is in connection with or following a change in control. Although the
definitions may vary slightly across these agreements, good reason generally means certain
demotions in responsibilities or title, decreases in compensation and/or relocation requirements,
while cause typically means conviction of a felony or a criminal act involving moral turpitude or
failure to follow lawful and proper instructions of the Board or CEO.
Severance generally consists of amount equal to the executives then current base salary (or,
for Mr. Balthrop the amount of base salary that would have been paid over the remainder of the
then-current term if greater) and the prior years bonus amount, less any payment or payments
received during the 12 month period from the time of termination under any long-term disability
plan. In addition, health or other employee benefits (other than bonus and incentive compensation
benefits) for the executive (and including Mr. Balthrops family) generally continue for a period
of twelve months following an executives termination to the extent permitted by the applicable
plans and law. If the termination occurs in connection with or following a change in control, Mr.
Balthrop is entitled to additional severance in an amount equal to the pro rated portion of the
current-year bonus to the extent the performance measures are achieved and Dr. Jacobson and Mr.
Marfin will instead receive 2.99 times their average annual base salary plus bonus for the most
recent five calendar years prior to the occurrence of the change of control. The employment
agreements for Dr. Jacobson and Mr. Marfin also provide for an additional payment to compensate
them for any tax liability imposed on change of control payments to the extent these payments
constitute parachute payments under Section 280G of the Code.
The severance payments are generally made upfront at the time of termination (or within six
months as described below) in a lump payment in order to make a clean separation from, and avoid
continued entanglement with, the employee. Additionally, certain of the employment agreements,
including Mr. Balthrops, were amended in 2006 to provide that in the event the payment of any
severance amounts payable pursuant to the employment agreements within six months of the date of
the applicable executives termination of employment would cause such executive to incur any
additional tax under Section 409A of the Code, then payment of such amounts shall be delayed until
the date that is six months following such executives termination date.
In addition, as described above, upon a change of control or a termination as a result of
death or disability, all unvested options or other restricted shares held by the executive will
immediately become vested and exercisable, as applicable, pursuant to these agreements.
Tables showing the potential payments and benefits under these employment agreements upon the
termination of our named executive officers are provided under Potential Payments Upon Termination
or Change in Control.
Each named executive officer has agreed to limitations on his ability to disclose confidential
information relating to us and acknowledges that all discoveries, inventions and other work product
relating to his employment belong to us. Also, during the one year period following an executives
termination of employment, each executive has agreed not to compete, directly or indirectly, with
the core business of the Company. Furthermore, during the non-compete period, each executive has
agreed not to solicit our employees or consultants.
The foregoing summaries are qualified in their entireties by reference to the complete texts
of the employment agreements previously filed by the Company with the SEC.
Historically, while each agreement has been the result of an arms-length negotiation, we have
tried to utilize a similar form of agreement where possible (apart from minimum salary and cash
bonus targets). Accordingly, Messrs. Marfin and Jacobson have substantially similar employment
agreements, as do Messrs. Currie and Reiter and our other executives (each hired more recently than
Messrs. Marfin and Jacobson), excluding Mr. Balthrop. Mr. Balthrops agreement varies to some
extent from the forms above and again reflects an arms-length negotiation following a lengthy CEO
search, and we believe the terms are appropriate in light of Mr. Balthrops background, skill set,
the difficulty in replacing Mr. Balthrop and the competitive nature of his recruitment process.
Retirement Plans. We match contributions by our named executive officers to our 401(k) plan
up to the maximum amount permitted under the Code.
19
MSPP. In 2006, the Committee approved, and the stockholders adopted, the MSPP to encourage
stock ownership and further align the interests of our senior officers and our stockholders.
Another goal of the MSPP is to enable us to utilize the cash saved in lieu of paying a portion of
annual performance bonuses for research and development and other productive corporate purposes.
The MSPP allows select executives to elect to receive, in lieu of a specified portion of his or her
annual performance bonus, a number of restricted shares equal to the amount of such specified
portion of the annual bonus divided by a dollar amount equal to 80% of the fair market value of a
share on the date on which such restricted shares are granted. Any participant who makes such an
election will be entitled to a grant of restricted shares generally by March 15 of each calendar
year following the year for which the election is in effect.
The restricted period for restricted shares granted under the MSPP is generally three years
from the date of grant. With respect to restricted shares granted under the MSPP, if a
participants employment is terminated during the restricted period, then, except as provided
below, the participants rights to such restricted shares will be entirely forfeited and the
participant will instead have the right to receive a cash payment equal to the lesser of (i) the
then-current fair market value of the restricted shares or (ii) the bonus amounts foregone by the
participant as a condition of receiving such restricted shares. If, during the restricted period,
termination of employment of a participant resulted from death or total and permanent disability,
the restrictions on the restricted shares will immediately lapse. If, during the restricted
period, a participant is terminated by the Company without cause, the participants right to the
restricted shares will be forfeited entirely and the participant will instead have the right to
receive a cash payment equal to either (i) the then-current fair market value of the restricted
shares or (ii) the bonus amounts foregone by the participant as a condition of receiving such
restricted shares. The Committee will decide, in its sole discretion, which of these amounts will
be payable. In addition, the Committee may, in its discretion, accelerate the lapse of such
restrictions upon a participants retirement.
No shares have been purchased to date under the MSPP.
Perquisites and Other Benefits. The Company does not generally provide perquisites that are
not, in the Committees view, integrally and directly related to the named executive officers
duties. Nor does the Company otherwise maintain retirement or deferred compensation programs for
executives other than participation in the Companys 401(k) plan and the MSPP as described above.
While we have no formal relocation policy for new hires, we will on occasion agree to reimbursement
of certain relocation and related costs as part of a negotiation for an executive based on the
particular facts and circumstances of the negotiation. Senior management also participates in our
other broad-based benefit programs available to our salaried employees including health, dental and
life insurance programs. Except as otherwise discussed herein, other welfare and employee-benefit
programs are generally the same for all eligible Company employees, including our executive
officers, with some variation as required by law with respect to our international employees.
Stock Ownership/Retention Guidelines. The Board believes that it is a responsibility of all
officers and directors of the Company to help achieve long-term stockholder value creation. In
furtherance of this goal and the Boards objective of adopting relevant corporate governance best
practices, the Company expects each officer and director to demonstrate a long-term commitment to
the Company and to the Companys stockholders by acquiring and holding a meaningful investment in
the Companys common stock. Therefore, the Board has established specific ownership and retention
guidelines for the Companys officers and directors, summarized below.
Over time each officer and director is expected to build his or her ownership of the Companys
common stock. The targeted ownership levels are expected to be achieved over five years from the
effective date of the program or from the time they are named an officer or a director, as
applicable, and maintained thereafter. The targeted ownership levels are as follows: CEO: five
(5) times annual salary; executive officers: two and one half (21/2) times annual salary;
non-employee directors: $100,000 market value. Each officer and director who has not yet achieved
the targeted ownership levels is expected to retain certain shares of common stock acquired upon
exercise of stock options or from restricted share grants pursuant to the Companys equity plans as
follows: (1) in the case of stock options exercised in 2006, directors and officers were expected
to hold the net number of shares acquired upon exercise of stock options for at least one year
after the exercise and retain at least 50% of those shares thereafter. Commencing in 2007,
directors and officers who have not achieved the targeted ownership requirements are expected to
hold a minimum of one-half the net number of shares acquired upon option exercises; and (2) in the
case of restricted shares, officers and directors are expected to hold, after each vesting date of
the award, at least one
half of the net vested shares.
20
The ownership guidelines may be achieved in any combination of the following manners:
purchases on the open market; shares owned jointly with or separately by spouse and/or children, or
held in trust for one of the foregoing persons; shares held through current or future employee
stock purchase or other retirement, profit sharing or pension plans adopted by the Company; shares
obtained through stock option exercises; and vested restricted shares.
The Board of Directors is authorized to make temporary exemptions to the foregoing ownership
guidelines in its discretion where compliance would impose a severe economic hardship or otherwise
prevent the officer or director from complying with a court order.
Accounting and Tax Matters. In part because of our lack of supplemental or top hat
retirement or deferred compensation plans (apart from the MSPP) typical of larger companies, we do
not presently consider the tax or accounting consequences to be a material factor in the design of
our executive compensation packages, except as to the applicability of Section 162(m) of the Code.
The compensation paid to our officers for 2006 did not exceed the $1 million limit per officer for
qualifying executive compensation for deductibility under Section 162(m), and it is not expected to
in 2007. Our Equity Plan is structured so that any compensation deemed paid to an officer when he
or she exercises an outstanding option under the Equity Plan with an exercise price equal to the
fair market value of the option shares on the grant date will qualify as performance-based
compensation which will not be subject to the $1 million limitation. Restricted share grants, for
which the vesting restrictions are solely time-based (including our CEOs performance-based
restricted share grant in light of the recent modification to include a cliff vesting feature at
the end of the five year performance period as described above), may not qualify as
performance-based compensation and could be subject to the $1 million limitation. The Balthrop
Option (see Narrative to Summary Compensation Table and Grants of Plan-Based Awards in 2006 Table
below) was not issued pursuant to a stockholder approved plan and, if exercised while Mr. Balthrop
is a covered employee, will not qualify as performance-based compensation and will therefore be
subject to the $1 million limitation. Although it will consider the tax implications of its
compensation decisions, the Committee believes its primary focus should be to attract, retain, and
motivate executives and to align the executives interests with those of the Companys
stakeholders. Accordingly, because the amount and mix of individual compensation are based on
competitive considerations as well as Company and individual performance, executive officer
compensation that is not performance-based may exceed $1.0 million in a given year.
The Committee operates its compensation programs with the good faith intention of complying
with Section 409A of the Code. Effective January 1, 2006, the Company began accounting for
stock-based payments with respect to its long-term equity incentive award programs in accordance
with the requirements of SFAS 123R.
Conclusion. The Committee takes its mandate and responsibilities very seriously and spends
considerable time assessing the overall executive compensation structure of the Company, reviewing
and approving corporate goals and objectives relating to the compensation of executive officers,
evaluating the performance of the executive officers and, where appropriate, making recommendations
for improving performance. In connection therewith, the Committee directly engaged independent
compensation consultants to assist the Committee in executing its responsibilities for 2006 and
2007. The Committees compensation philosophy for an executive officer is intended to reward
performance, while reflecting the unique attributes of the Company and each employee individually.
Our executive compensation program is also structured to be competitive within our peer group and
is specifically designed around various components of compensation intended to promote our
compensation objectives.
Our approach to executive compensation emphasizes significant time and performance-based
elements intended to promote long-term stockholder value and, in our view, appropriately aligns the
interests of the Companys executive officers with those of the Companys stockholders.
Additionally, we have adopted stock ownership guidelines to ensure our executives maintain a
significant stake in our long-term performance. At the same time, we recognize that a proper
executive compensation program should also be designed to attract, motivate, reward and retain the
talent required to execute the Companys business strategy. We believe our executive compensation
programs create an effective balance between these various objectives and promote the long-term
value and health of the Company.
21
Compensation Committee Report On Executive Compensation
The Compensation Committee has reviewed the Compensation Discussion and Analysis and discussed
it with management and, based on such review and discussion, recommended to the Board of Directors
that the Compensation Discussion and Analysis be included in this proxy statement and incorporated
by reference into the Companys Annual Report on Form 10-K.
Submitted by the Compensation Committee of the Board of Directors,
Jay B. Johnston (Chairman)
Fred C. Goad, Jr.
Jim D. Kever
Gerard Vaillant
Summary Compensation Table
The following table sets forth certain summary information for the year ending December 31,
2006, with respect to the compensation awarded to, earned by, or paid to our named executive
officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock |
|
Option |
|
Plan |
|
All Other |
|
|
Name and |
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards |
|
Awards |
|
Compensation |
|
Compensation |
|
|
Principal Position |
|
Year |
|
Salary ($) |
|
Bonus ($) |
|
($) (2) |
|
($) (3) |
|
($) (4) |
|
($) (5) |
|
Total ($) |
Patrick J. Balthrop, Sr. |
|
|
2006 |
|
|
|
400,000 |
|
|
|
192,496 |
(1) |
|
|
569,586 |
|
|
|
893,472 |
|
|
|
337,000 |
|
|
|
7,292 |
|
|
|
2,399,846 |
|
President & Chief
Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Harriss T. Currie |
|
|
2006 |
|
|
|
228,800 |
|
|
|
|
|
|
|
71,029 |
|
|
|
253,634 |
|
|
|
141,376 |
|
|
|
5,000 |
|
|
|
699,839 |
|
Vice President,
Finance, Chief
Financial Officer
and Treasurer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Randel S. Marfin |
|
|
2006 |
|
|
|
225,500 |
|
|
|
|
|
|
|
59,364 |
|
|
|
174,578 |
|
|
|
108,217 |
|
|
|
3,333 |
|
|
|
570,992 |
|
Vice President,
Luminex Bioscience
Group |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James W. Jacobson, Ph.D. |
|
|
2006 |
|
|
|
226,150 |
|
|
|
|
|
|
|
59,364 |
|
|
|
123,737 |
|
|
|
140,915 |
|
|
|
3,385 |
|
|
|
553,551 |
|
Vice President,
Research and
Development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David S. Reiter |
|
|
2006 |
|
|
|
214,200 |
|
|
|
|
|
|
|
48,092 |
|
|
|
274,091 |
|
|
|
133,854 |
|
|
|
7,500 |
|
|
|
677,737 |
|
Vice President,
General Counsel and
Corporate Secretary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Reflects a subjective, discretionary bonus of $100,000 awarded to Mr. Balthrop in 2007
relating to 2006 performance as further described above under Compensation Discussion and
Analysis Executive Compensation for 2006. This amount also includes the 2006 installments
of the payments to Mr. Balthrop in connection with the repricing of his sign-on option grant
in 2005 as described below under Narrative to Summary Compensation Table and Grants of
Plan-Based Awards in 2006 Table. |
|
(2) |
|
The amounts shown in this column represent the dollar amounts recognized for financial
statement reporting in 2006 and thus include amounts from awards granted in and prior to 2006.
Assumptions used in the calculation of these amounts are described in Note 12 to the
Companys audited financial statements for the fiscal year ended December 31, 2006, included
in the Companys Annual Report on Form 10-K that was filed with the SEC on March 16, 2007.
All grants of restricted stock were made under the Companys 2000 Long-Term Incentive Plan
(the 2000 Plan) and are subject to individual award agreements, the forms of which were
previously filed with the SEC. During 2006, there were no forfeitures of restricted stock
awards related to service-based vesting conditions for the named executive officers. Mr.
Balthrops 200,000 share restricted stock award, as amended, has market/service or
performance/service criteria for vesting of all shares. We have assumed that vesting will
occur at the end of the five years based on achievement of the market and/or |
22
|
|
|
|
|
performance criteria so all expense is being amortized straight-line over the five-year period
ending May 17, 2004 through 2009. Pursuant to the amendment to this award described below
under Outstanding Equity Awards At 2006 Fiscal Year-End, any unvested shares shall cliff
vest immediately prior to the fifth anniversary of the original grant date. |
|
(3) |
|
The amounts shown in this column represent the dollar amounts recognized for financial
statement reporting purposes for the fiscal year ended December 31, 2006 in accordance with
SFAS 123R (calculated, per the SEC rules, without consideration of the impact of estimated
forfeitures related to service-based vesting conditions) and thus include amounts from awards
granted in and prior to 2006. Assumptions used in the calculation of these amounts are
described in Note 12 to the Companys audited financial statements for the fiscal year ended
December 31, 2006, included in the Companys Annual Report on Form 10-K. All grants of options
to purchase the Companys common stock were made under the 2000 Plan or predecessor plans and
are subject to individual award agreements, the forms of which were previously filed with the
SEC, except that the Balthrop Option (see below under Narrative to Summary Compensation Table
and Grants of Plan-Based Awards in 2006 Table) was not issued pursuant to a stockholder
approved plan. During 2006, there were no forfeitures of option awards related to
service-based vesting conditions for the named executive officers. |
|
(4) |
|
The amounts shown in this column reflect 2006 annual cash-based incentive bonuses earned by
each of the named executive officers pursuant to the Companys 2006 management incentive
plans, which are discussed in further detail under Compensation Discussion and Analysis
Executive Compensation for 2006. The potential payouts under these plans at the time the
plans were established in 2006 are provided below under Grants of Plan-Based Awards in 2006. |
|
(5) |
|
This column includes matching payments under our 401(k) Plan. |
Grants Of Plan-Based Awards in 2006
The following table summarizes grants of plan-based awards made to our named executive
officers in 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant |
|
|
|
|
|
|
Estimated Possible Payouts |
|
All Other Stock Awards: |
|
Date |
|
|
|
|
|
|
Under Non-Equity Incentive |
|
Number of Shares of |
|
Fair Value |
|
|
|
|
|
|
Plan Awards (1) |
|
Stock |
|
of Stock |
Name |
|
Grant Date |
|
Threshold ($) |
|
Target ($) |
|
Maximum ($) |
|
or Units (#) (2) |
|
Awards ($) (3) |
Patrick J. Balthrop, Sr. |
|
|
04/05/2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32,000 |
|
|
|
463,360 |
|
|
|
|
N/A |
|
|
|
|
|
|
|
400,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Harriss T. Currie |
|
|
04/05/2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,772 |
|
|
|
213,899 |
|
|
|
|
N/A |
|
|
|
57,200 |
|
|
|
114,400 |
|
|
|
171,600 |
|
|
|
|
|
|
|
|
|
Randel S. Marfin |
|
|
04/05/2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,324 |
|
|
|
135,012 |
|
|
|
|
N/A |
|
|
|
56,375 |
|
|
|
112,750 |
|
|
|
169,125 |
|
|
|
|
|
|
|
|
|
James W. Jacobson, Ph.D. |
|
|
04/05/2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,324 |
|
|
|
135,012 |
|
|
|
|
N/A |
|
|
|
56,538 |
|
|
|
113,075 |
|
|
|
169,613 |
|
|
|
|
|
|
|
|
|
David S. Reiter |
|
|
04/05/2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,855 |
|
|
|
128,220 |
|
|
|
|
N/A |
|
|
|
53,550 |
|
|
|
107,100 |
|
|
|
160,650 |
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The amounts shown in these columns reflect the threshold (25% of base salary), target (50%
of base salary) and maximum (75% of base salary) amounts (assuming threshold, target and
maximum performance across all performance objectives were achieved) that each of the named
executive officers (other than our CEO) could have earned for the fiscal year ended December
31, 2006 pursuant to the Companys 2006 management incentive plans. Mr. Balthrops bonus
plan for 2006 did not provide for an over/underachievement scale providing for payments above
or below the target bonus amount provided in this table under the Target column. The terms
of our named executive officer bonus plans, including Mr. Balthrops subjective,
discretionary bonus for 2006 are discussed in further detail in Compensation Discussion and
Analysis Executive Compensation for 2006. The amounts actually awarded to each of the
named executive officers are reflected in the Summary Compensation Table above. |
|
(2) |
|
The amounts in this column represent restricted stock grants made to each of the named
executive officers during the fiscal year ended December 31, 2006 pursuant to the 2000 Plan.
The restrictions applicable to |
23
|
|
|
|
|
these awards lapse with respect to 1/5th of the total shares subject to the grant
each year, beginning on the anniversary of the grant date. |
|
(3) |
|
Determined by reference to the closing market price of our common stock on the NASDAQ
Global Market on the date of grant ($14.48). |
Narrative to Summary Compensation Table and Grants of Plan-Based Awards in 2006 Table
The following discussion is intended to be read as a supplement to the Summary Compensation
Table and the Grants of Plan-Based Awards in 2006 table (including the notes to such tables),
and to the disclosure under Compensation Discussion and Analysis, and the following discussion
should be read in conjunction with such other disclosures.
Compensation Mix
As reflected in the Summary Compensation Table and Grants of Plan-Based Awards in 2006
table, the primary components of the Companys 2006 compensation program for our named executive
officers were cash compensation, consisting of a mix of base salary and cash incentive plan
compensation, and equity incentive compensation, consisting of restricted stock with time-based
vesting. Generally, and excluding the Companys CEO, bonus compensation for 2006 was 23% to 28% of
the total of these elements, while the value of equity awards, valued at fair market value on the
date of grant, for 2006 represented 27% to 36% of the total compensation opportunities for 2006.
As for the CEO, Mr. Balthrops bonus compensation for 2006 was 38% of the total of these elements
and his equity award, valued at fair market value on the date of grant, for 2006 was 33% of the
total compensation elements. For a detailed discussion of each of these components and explanation
of how the level of each of these elements of compensation is generally determined in relation to
an executives total compensation, see Compensation Discussion and Analysis Program Design
Primary Elements and Compensation Mix.
Option Repricing
Mr. Balthrop was hired as the Companys chief executive officer and president on May 15, 2004.
In connection therewith, Mr. Balthrop was granted a non-qualified stock option to purchase 500,000
shares of common of the Company (the Balthrop Option). The Balthrop Option is subject to
time-based vesting, provided Mr. Balthrop continues in the employment of the Company, with 125,000
shares vested as of May 15, 2005, and the remaining shares vesting in equal increments over the
following 36 months. The Balthrop Option was initially granted at an exercise price of $9.36 per
share. As previously reported, at a meeting of the Committee on February 10, 2005, the Committee
approved resolutions to increase the exercise price of the Balthrop Option from $9.36 per share to
$10.10 per share (the closing market price on the date immediately preceding the original grant
date). This modification was made in order to eliminate the potential application of certain
adverse tax implications in light of tax law changes created as a result of the American Jobs
Creation Action of 2004. In connection therewith, the Compensation Committee of our Board of
Directors approved a cash bonus payable to Mr. Balthrop to be paid consistent with the vesting
period of the Balthrop Option, subject to Mr. Balthrops continued employment, equal to $370,000.
According to the vesting schedule and assuming no acceleration event contemplated by the Balthrop
Option, one quarter of the cash bonus was paid as of May 15, 2005 (the first vesting date and under
the Balthrop Option) and the balance of such payments are being made in equal monthly installments
over the 36 months thereafter and are reflected in the Bonus column of the Summary Compensation
Table.
Employment Agreements
We have entered into employment agreements with each of our named executive officers, each
previously filed with the SEC. The employment agreements provide for certain salary, annual bonus
opportunities and other benefits, including potential severance entitlements. The employment
agreements with Messrs. Balthrop, Currie and Reiter are generally automatically renewable on an
annual basis unless either party provides the other written notice of its intent not to renew the
agreement at least 60 (in the case of Messrs. Currie and Reiter), or 180 (for Mr. Balthrop), days
prior to the end of the then-current term of their agreements. The agreements with Messrs. Marfin
and Jacobsen also automatically renew annually and do not provide a non-renewal notice/option, but
they may be terminated by us at any time, subject to our severance payment obligations. These
agreements are described in more detail under Compensation Discussion and Analysis Change in
Control; Termination Benefits. The potential
24
payouts under these agreements in connection with the termination of these executives is provided
under Potential Payments Upon Termination or Change in Control.
Outstanding Equity Awards At 2006 Fiscal Year-End
The following table summarizes the number of outstanding equity awards held by each of our
named executive officers as of December 31, 2006. The market value of shares was calculated using
the year-end closing price of $12.70 as reported on the NASDAQ Global Market.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards |
|
Stock Awards |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Market |
|
Incentive Plan |
|
Incentive Plan |
|
|
Number of |
|
Number of |
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of |
|
Value of |
|
Awards: |
|
Awards: |
|
|
Securities |
|
Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares or |
|
Shares or |
|
Number of |
|
Market Value |
|
|
Underlying |
|
Underlying |
|
|
|
|
|
|
|
|
|
|
|
|
|
Units of |
|
Units of |
|
Unearned |
|
of Unearned |
|
|
Unexercised |
|
Unexercised |
|
Option |
|
Option |
|
Option |
|
Stock That |
|
Stock That |
|
Shares That |
|
Shares That |
|
|
Options (#) |
|
Options (#) |
|
Exercise |
|
Grant |
|
Expiration |
|
Have Not |
|
Have Not |
|
Have Not |
|
Have Not |
Name |
|
Exercisable |
|
Unexercisable |
|
Price ($) |
|
Date |
|
Date (1) |
|
Vested (#) (2) |
|
Vested ($) |
|
Vested (#) |
|
Vested ($) |
Patrick J. Balthrop, Sr. |
|
|
312,506 |
|
|
|
187,494 |
|
|
|
10.10 |
|
|
|
05/15/2004 |
|
|
|
05/15/2014 |
(3) |
|
|
32,000 |
|
|
|
406,400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000 |
(4) |
|
|
2,540,000 |
|
Harriss T. Currie |
|
|
10,000 |
|
|
|
|
|
|
|
17.00 |
|
|
|
03/15/2000 |
|
|
|
03/15/2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,000 |
|
|
|
|
|
|
|
13.05 |
|
|
|
04/25/2001 |
|
|
|
04/25/2011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000 |
|
|
|
|
|
|
|
6.52 |
|
|
|
05/23/2002 |
|
|
|
05/23/2012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56,250 |
|
|
|
18,750 |
|
|
|
4.68 |
|
|
|
03/17/2003 |
|
|
|
03/17/2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67,298 |
|
|
|
17,702 |
|
|
|
8.41 |
|
|
|
10/13/2003 |
|
|
|
10/13/2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,312 |
|
|
|
4,688 |
|
|
|
8.22 |
|
|
|
03/25/2004 |
|
|
|
03/25/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500 |
|
|
|
31,750 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,484 |
|
|
|
196,647 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,772 |
|
|
|
187,604 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Randel S. Marfin |
|
|
40,000 |
|
|
|
|
|
|
|
17.00 |
|
|
|
03/15/2000 |
|
|
|
03/15/2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000 |
|
|
|
|
|
|
|
25.06 |
|
|
|
12/05/2000 |
|
|
|
12/05/2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000 |
|
|
|
|
|
|
|
24.81 |
|
|
|
01/19/2001 |
|
|
|
01/19/2011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,000 |
|
|
|
37,500 |
|
|
|
4.68 |
|
|
|
03/17/2003 |
|
|
|
03/17/2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,312 |
|
|
|
4,688 |
|
|
|
8.22 |
|
|
|
03/25/2004 |
|
|
|
03/25/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500 |
|
|
|
31,750 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,484 |
|
|
|
196,647 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,324 |
|
|
|
118,415 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James W. Jacobson, Ph.D. |
|
|
12,500 |
|
|
|
|
|
|
|
17.00 |
|
|
|
03/15/2000 |
|
|
|
03/15/2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,220 |
|
|
|
|
|
|
|
13.05 |
|
|
|
04/25/2001 |
|
|
|
04/25/2011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000 |
|
|
|
|
|
|
|
6.52 |
|
|
|
05/23/2002 |
|
|
|
05/23/2012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,000 |
|
|
|
25,000 |
|
|
|
4.68 |
|
|
|
03/17/2003 |
|
|
|
03/17/2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,312 |
|
|
|
4,688 |
|
|
|
8.22 |
|
|
|
03/25/2004 |
|
|
|
03/25/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500 |
|
|
|
31,750 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,484 |
|
|
|
196,647 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,324 |
|
|
|
118,415 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David S. Reiter |
|
|
7,500 |
|
|
|
2,500 |
|
|
|
6.79 |
|
|
|
08/29/2003 |
|
|
|
08/29/2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,562 |
|
|
|
3,438 |
|
|
|
6.67 |
|
|
|
09/30/2003 |
|
|
|
09/30/2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,787 |
|
|
|
1,268 |
|
|
|
8.41 |
|
|
|
10/13/2003 |
|
|
|
10/13/2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,484 |
|
|
|
196,647 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,855 |
|
|
|
112,459 |
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Except as provided in footnote (3) with respect to the Balthrop Option, all options vest
in equal 1/4th increments on each anniversary of the grant date over the first
four years of the option term. |
|
(2) |
|
The restrictions applicable to these awards lapse with respect to 1/5th of the
total shares subject to the grant each year on each anniversary of the grant date, beginning
on the anniversary of the grant date. |
|
(3) |
|
The Balthrop Option is subject to time-based vesting, with an initial 125,000 shares
vested as of May 15, 2005, and the remaining shares vesting in equal monthly increments over
the following 36 months. |
|
(4) |
|
Mr. Balthrop was granted a restricted stock award for 200,000 shares of the Companys
common stock under the 2000 Plan in connection with his hiring in 2004. The restricted
stock is subject to various performance related vesting criteria over a period of five years
as follows: (i) 1/3rd of the grant vests based upon the Companys common stock
trading price, (ii) 1/3rd of the grant vests based upon the achievement of
certain revenue targets, and (iii) 1/3rd of the grant vests based upon the
achievement of certain earnings before interest, taxes, depreciation, and amortization
measures. As previously discussed, the Compensation Committee determined at a meeting in
March 2007 that it would be in the best interests of the Company to amend the restricted
stock agreement to provide for the automatic vesting of all unvested restricted shares |
25
|
|
|
|
|
immediately prior to the fifth anniversary of the date of the restricted stock agreement, to
the extent any or all of the performance measures have not been previously achieved. |
Option Exercises And Stock Vested in 2006
The following table sets forth information regarding the exercise of stock options and the
vesting of restricted stock awards during the fiscal year ended December 31, 2006 for each of the
named executive officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards |
|
Stock Awards |
|
|
Number of |
|
|
|
|
|
Number |
|
|
|
|
Shares |
|
|
|
|
|
of Shares |
|
Value |
|
|
Acquired |
|
Value Realized |
|
Acquired |
|
Realized on |
Name |
|
on Exercise (#) |
|
on Exercise ($) (1) |
|
on Vesting (#) |
|
Vesting ($) (1) |
Patrick J. Balthrop (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Harriss T. Currie (3) |
|
|
|
|
|
|
|
|
|
|
5,121 |
|
|
|
75,423 |
|
Randal S. Marfin (4) |
|
|
62,500 |
|
|
|
786,500 |
|
|
|
5,121 |
|
|
|
75,423 |
|
James W. Jacobson, Ph.D. (5) |
|
|
|
|
|
|
|
|
|
|
5,121 |
|
|
|
75,423 |
|
David S. Reiter (6) |
|
|
10,000 |
|
|
|
142,020 |
|
|
|
3,871 |
|
|
|
57,523 |
|
|
|
|
(1) |
|
The value realized on exercise, or upon the vesting of restricted shares, shown in the
table is calculated based upon the closing price of our common stock on the NASDAQ Global
Market on the exercise or vesting date, as applicable. |
|
(2) |
|
Mr. Balthrop exercised no options in 2006. None of Mr. Balthrops restricted shares
vested during 2006. |
|
(3) |
|
Mr. Currie exercised no options in 2006. Additionally, 5,121 of Mr. Curries restricted
shares vested during 2006. |
|
(4) |
|
Mr. Marfin exercised 62,500 options with a weighted average exercise price of $5.42 per
share in 2006. Additionally, 5,121 of Mr. Marfins restricted shares vested during 2006. |
|
(5) |
|
Dr. Jacobson exercised no options in 2006. Additionally, 5,121 of Dr. Jacobsons
restricted shares vested during 2006. |
|
(6) |
|
Mr. Reiter exercised 10,000 options with a weighted average exercise price of $5.30 per
share in 2006. Additionally, 3,871 of Mr. Reiters restricted shares vested during 2006. |
26
Potential Payments Upon Termination or Change in Control
The following tables show for each of our named executive officers the estimated amount of
potential payments, as well as estimated value of continuing benefits, assuming the executives
employment terminates effective December 31, 2006 and based on compensation and benefit levels in
effect on December 31, 2006. Due to the numerous factors involved in estimating these amounts, the
actual benefits and amounts payable can only be determined at the time of an executives
termination from the Company.
Patrick J. Balthrop
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
Termination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Without |
|
|
|
|
|
in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cause or |
|
|
|
|
|
Connection |
|
|
|
|
Executive Benefits and |
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
with a |
|
|
|
|
Payments Upon |
|
Voluntary |
|
|
|
|
|
for Good |
|
For Cause |
|
Change in |
|
|
|
|
Separation |
|
Termination |
|
Retirement |
|
Reason |
|
Termination |
|
Control |
|
Disability |
|
Death |
Cash Severance (1) |
|
|
|
|
|
|
|
|
|
|
400,000 |
|
|
|
|
|
|
|
400,000 |
|
|
|
400,000 |
|
|
|
400,000 |
|
Non-equity
Incentive
Compensation
(Bonus) (1) |
|
|
|
|
|
|
|
|
|
|
400,000 |
|
|
|
|
|
|
|
400,000 |
|
|
|
400,000 |
|
|
|
400,000 |
|
Accelerated Vesting
of Options (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,265,547 |
|
|
|
|
|
|
|
|
|
Accelerated Vesting
of Restricted Stock
(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,352,852 |
|
|
|
|
|
|
|
|
|
Continuation of
Insurance Benefits
(3) |
|
|
|
|
|
|
|
|
|
|
74,686 |
|
|
|
|
|
|
|
74,686 |
|
|
|
42,951 |
|
|
|
20,000 |
|
Accrued Vacation Pay |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise Tax Gross-Up |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
(1) |
|
The cash severance entitlement is described under Compensation Discussion and Analysis
Change in Control; Termination Benefits. |
|
(2) |
|
Accelerated vesting of stock options and restricted stock is triggered upon a change of
control (whether or not the executives employment is terminated) or the death or disability
of the executive. Accelerated vesting of stock option amounts are calculated as the
difference between the closing market price of our common stock on December 29, 2006 ($12.70
per share as reported on the NASDAQ Global Market) and the respective exercise prices of
in-the-money unvested stock options. The closing market price on December 29, 2006 is also
used to calculate accelerated vesting of restricted stock amounts. |
|
(3) |
|
Reflects the present value of the medical premiums the executive would be entitled to for a
period of 12 months following the termination date, and the estimated lump sum present value
of the disability and life insurance payments the executive would be entitled to. Amounts are
based upon the types of insurance coverage the Company carried for such executive as of
December 31, 2006 and the premiums in effect on such date. |
27
Harriss T. Currie
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
Termination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Without |
|
|
|
|
|
in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cause or |
|
|
|
|
|
Connection |
|
|
|
|
Executive Benefits and |
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
with a |
|
|
|
|
Payments Upon |
|
Voluntary |
|
|
|
|
|
for Good |
|
For Cause |
|
Change in |
|
|
|
|
Separation |
|
Termination |
|
Retirement |
|
Reason |
|
Termination |
|
Control |
|
Disability |
|
Death |
Cash Severance (1) |
|
|
|
|
|
|
|
|
|
|
228,800 |
|
|
|
|
|
|
|
228,800 |
|
|
|
228,800 |
|
|
|
228,800 |
|
Non-equity Incentive
Compensation (Bonus) (1) |
|
|
|
|
|
|
|
|
|
|
114,400 |
|
|
|
|
|
|
|
114,400 |
|
|
|
114,400 |
|
|
|
114,400 |
|
Accelerated Vesting of
Options (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
164,770 |
|
|
|
|
|
|
|
|
|
Accelerated Vesting of
Restricted Stock (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
289,591 |
|
|
|
|
|
|
|
|
|
Continuation of Insurance
Benefits (3) |
|
|
|
|
|
|
|
|
|
|
74,686 |
|
|
|
|
|
|
|
74,686 |
|
|
|
74,686 |
|
|
|
20,000 |
|
Accrued Vacation Pay |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise Tax Gross-Up |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
(1) |
|
The cash severance entitlement is described under Compensation Discussion and Analysis
Change in Control; Termination Benefits. |
|
(2) |
|
Accelerated vesting of stock options and restricted stock is triggered upon a change of
control (whether or not the executives employment is terminated) or the death or disability
of the executive. Accelerated vesting of stock option amounts are calculated as the
difference between the closing market price of our common stock on December 29, 2006 ($12.70
per share as reported on the NASDAQ Global Market) and the respective exercise prices of
in-the-money unvested stock options. The closing market price on December 29, 2006 is also
used to calculate accelerated vesting of restricted stock amounts. |
|
(3) |
|
Reflects the present value of the medical premiums the executive would be entitled to for a
period of 12 months following the termination date, and the estimated lump sum present value
of the disability and life insurance payments the executive would be entitled to. Amounts are
based upon the types of insurance coverage the Company carried for such executive as of
December 31, 2006 and the premiums in effect on such date. |
28
Randel S. Marfin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary |
|
|
|
|
|
Connection |
|
|
|
|
Executive Benefits and |
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
with a |
|
|
|
|
Payments Upon |
|
Voluntary |
|
|
|
|
|
Without |
|
For Cause |
|
Change in |
|
|
|
|
Separation |
|
Termination |
|
Retirement |
|
Cause |
|
Termination |
|
Control |
|
Disability |
|
Death |
Cash Severance (1) |
|
|
|
|
|
|
|
|
|
|
225,500 |
|
|
|
|
|
|
|
605,089 |
|
|
|
|
|
|
|
|
|
Non-equity Incentive
Compensation (Bonus) (1) |
|
|
|
|
|
|
|
|
|
|
112,750 |
|
|
|
|
|
|
|
267,076 |
|
|
|
|
|
|
|
|
|
Accelerated Vesting of
Options (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58,948 |
|
|
|
|
|
|
|
|
|
Accelerated Vesting of
Restricted Stock (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
222,368 |
|
|
|
|
|
|
|
|
|
Continuation of Insurance
Benefits (3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000 |
|
Accrued Vacation Pay |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise Tax Gross-Up |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
0 |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
(1) |
|
The cash severance entitlement is described under Compensation Discussion and Analysis
Change in Control; Termination Benefits. |
|
(2) |
|
Accelerated vesting of stock options and restricted stock is triggered upon a change of
control (whether or not the executives employment is terminated) or the death or disability
of the executive. Accelerated vesting of stock option amounts are calculated as the
difference between the closing market price of our common stock on December 29, 2006 ($12.70
per share as reported on the NASDAQ Global Market) and the respective exercise prices of
in-the-money unvested stock options. The closing market price on December 29, 2006 is also
used to calculate accelerated vesting of restricted stock amounts. |
|
(3) |
|
Reflects the present value of the medical premiums the executive would be entitled to for a
period of 12 months following the termination date, and the estimated lump sum present value
of the disability and life insurance payments the executive would be entitled to. Amounts are
based upon the types of insurance coverage the Company carried for such executive as of
December 31, 2006 and the premiums in effect on such date. |
29
James W. Jacobson, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary |
|
|
|
|
|
Connection |
|
|
|
|
Executive Benefits and |
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
with a |
|
|
|
|
Payments Upon |
|
Voluntary |
|
|
|
|
|
Without |
|
For Cause |
|
Change in |
|
|
|
|
Separation |
|
Termination |
|
Retirement |
|
Cause |
|
Termination |
|
Control |
|
Disability |
|
Death |
Cash Severance (1) |
|
|
|
|
|
|
|
|
|
|
226,150 |
|
|
|
|
|
|
|
556,442 |
|
|
|
|
|
|
|
|
|
Non-equity Incentive
Compensation (Bonus) (1) |
|
|
|
|
|
|
|
|
|
|
113,075 |
|
|
|
|
|
|
|
257,858 |
|
|
|
|
|
|
|
|
|
Accelerated Vesting of
Options (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
48,362 |
|
|
|
|
|
|
|
|
|
Accelerated Vesting of
Restricted Stock (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
222,368 |
|
|
|
|
|
|
|
|
|
Continuation of Insurance
Benefits (3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000 |
|
Accrued Vacation Pay |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise Tax Gross-Up |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
0 |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
(1) |
|
The cash severance entitlement is described under Compensation Discussion and Analysis
Change in Control; Termination Benefits. |
|
(2) |
|
Accelerated vesting of stock options and restricted stock is triggered upon a change of
control (whether or not the executives employment is terminated) or the death or disability
of the executive. Accelerated vesting of stock option amounts are calculated as the
difference between the closing market price of our common stock on December 29, 2006 ($12.70
per share as reported on the NASDAQ Global Market) and the respective exercise prices of
in-the-money unvested stock options. The closing market price on December 29, 2006 is also
used to calculate accelerated vesting of restricted stock amounts. |
|
(3) |
|
Reflects the present value of the medical premiums the executive would be entitled to for a
period of 12 months following the termination date, and the estimated lump sum present value
of the disability and life insurance payments the executive would be entitled to. Amounts are
based upon the types of insurance coverage the Company carried for such executive as of
December 31, 2006 and the premiums in effect on such date. |
30
David S. Reiter
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
Termination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Without |
|
|
|
|
|
in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cause or |
|
|
|
|
|
Connection |
|
|
|
|
Executive Benefits and |
|
|
|
|
|
|
|
|
|
Termination |
|
|
|
|
|
with a |
|
|
|
|
Payments Upon |
|
Voluntary |
|
|
|
|
|
for Good |
|
For Cause |
|
Change in |
|
|
|
|
Separation |
|
Termination |
|
Retirement |
|
Reason |
|
Termination |
|
Control |
|
Disability |
|
Death |
Cash Severance (1) |
|
|
|
|
|
|
|
|
|
|
214,200 |
|
|
|
|
|
|
|
214,200 |
|
|
|
214,200 |
|
|
|
214,200 |
|
Non-equity Incentive
Compensation (Bonus) (1) |
|
|
|
|
|
|
|
|
|
|
107,100 |
|
|
|
|
|
|
|
107,100 |
|
|
|
107,100 |
|
|
|
107,100 |
|
Accelerated Vesting of
Options (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214,767 |
|
|
|
|
|
|
|
|
|
Accelerated Vesting of
Restricted Stock (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
203,922 |
|
|
|
|
|
|
|
|
|
Continuation of Insurance
Benefits (3) |
|
|
|
|
|
|
|
|
|
|
74,686 |
|
|
|
|
|
|
|
74,686 |
|
|
|
74,686 |
|
|
|
20,000 |
|
Accrued Vacation Pay |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise Tax Gross-Up |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
(1) |
|
The cash severance entitlement is described under Compensation Discussion and Analysis
Change in Control; Termination Benefits. |
|
(2) |
|
Accelerated vesting of stock options and restricted stock is triggered upon a change of
control (whether or not the executives employment is terminated) or the death or disability
of the executive. Accelerated vesting of stock option amounts are calculated as the
difference between the closing market price of our common stock on December 29, 2006 ($12.70
per share as reported on the NASDAQ Global Market) and the respective exercise prices of
in-the-money unvested stock options. The closing market price on December 29, 2006 is also
used to calculate accelerated vesting of restricted stock amounts. |
|
(3) |
|
Reflects the present value of the medical premiums the executive would be entitled to for a
period of 12 months following the termination date, and the estimated lump sum present value
of the disability and life insurance payments the executive would be entitled to. Amounts are
based upon the types of insurance coverage the Company carried for such executive as of
December 31, 2006 and the premiums in effect on such date. |
31
Director Compensation for 2006
The following table summarizes the compensation paid with respect to the fiscal year ended
December 31, 2006 to each of the Companys non-employee directors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees |
|
|
|
|
|
|
|
|
|
|
Earned |
|
|
|
|
|
|
|
|
|
|
or |
|
|
|
|
|
|
|
|
|
|
Paid in |
|
Stock |
|
Option |
|
All Other |
|
|
Name |
|
Cash ($) |
|
Awards ($) (1) |
|
Awards ($) (2) |
|
Compensation ($) |
|
Total ($) |
G. Walter Loewenbaum II |
|
|
136,000 |
|
|
|
238,333 |
|
|
|
|
|
|
|
|
|
|
|
374,333 |
|
Thomas W. Erickson |
|
|
54,000 |
|
|
|
112,546 |
|
|
|
|
|
|
|
|
|
|
|
166,546 |
|
Robert J. Cresci |
|
|
61,000 |
|
|
|
86,065 |
|
|
|
|
|
|
|
|
|
|
|
147,065 |
|
Fred C. Goad, Jr. |
|
|
45,000 |
|
|
|
59,583 |
|
|
|
|
|
|
|
|
|
|
|
104,583 |
|
Gerard Vaillant |
|
|
36,500 |
|
|
|
59,583 |
|
|
|
8,021 |
|
|
|
|
|
|
|
104,104 |
|
Jim D. Kever |
|
|
48,000 |
|
|
|
74,959 |
|
|
|
|
|
|
|
|
|
|
|
122,959 |
|
Kevin M. McNamara |
|
|
45,000 |
|
|
|
97,170 |
|
|
|
|
|
|
|
|
|
|
|
142,170 |
|
J. Stark Thompson |
|
|
45,000 |
|
|
|
117,824 |
|
|
|
|
|
|
|
|
|
|
|
162,824 |
|
Jay B. Johnston |
|
|
52,000 |
|
|
|
86,065 |
|
|
|
8,021 |
|
|
|
|
|
|
|
146,086 |
|
|
|
|
(1) |
|
The amounts shown in this column represent the dollar amounts recognized for financial
statement reporting purposes for the fiscal year ended December 31, 2006 and thus include
amounts from awards granted in and prior to 2006. Assumptions used in the calculation of
these amounts are described in Note 12 to the Companys audited financial statements for the
fiscal year ended December 31, 2006, included in the Companys Annual Report on Form 10-K.
All grants of restricted shares were made under the 2000 Plan and are subject to individual
award agreements, the forms of which were previously filed with the SEC. The grant date fair
value of the aggregate restricted stock awards granted to our non-employee directors in 2006
was: Loewenbaum $280,620, Erickson $132,515, Cresci $101,335, Goad $70,155, Vaillant
$70,155, Kever $70,155, McNamara $132,515, Thompson $158,080, and Johnston
$101,335. As of December 31, 2006, the aggregate number of unvested restricted shares
outstanding for each of the Companys non-employee directors was as follows: Loewenbaum
18,000, Erickson 8,500, Cresci 6,500, Goad 4,500, Vaillant 4,500, Kever 4,500,
McNamara 8,500, Thompson 6,500, and Johnston 6,500. |
|
(2) |
|
The amounts shown in this column represent the dollar amounts recognized for financial
statement reporting purposes for the fiscal year ended December 31, 2006 in accordance with
SFAS 123R (calculated, per the SEC rules, without consideration of the impact of estimated
forfeitures related to service-based vesting conditions) and thus include amounts from awards
granted prior to 2006. oAssumptions used in the calculation of these amounts are described
in Note 12 to the Companys audited financial statements for the fiscal year ended December
31, 2006, included in the Companys Annual Report on Form 10-K. All grants of options to
purchase the Companys common stock were made under the 2000 Plan or predecessor plans and
are subject to individual award agreements, the forms of which were previously filed with the
SEC. During 2006, no options were granted to our directors. As of December 31, 2006, the
aggregate number of shares subject to option awards outstanding for each of the Companys
non-employee directors was as follows: Loewenbaum 100,000, Erickson 262,500, Cresci
45,200, Goad 10,000, Vaillant 15,000, Kever 45,200, McNamara 95,000, Thompson 0,
and Johnston 15,000. The intrinsic value of these awards, as of December 31, 2006, were
$478,240, $1,572,925, $216,564, $0, $78,300, $216,564, $401,750, $0, and $78,300,
respectively, calculated based on the difference between the market value of our common stock
at year end (as reported on the NASDAQ Global Market) and the applicable weighted average
exercise price of these options. |
32
Narrative to Director Compensation Table
Following the completion of its review of the appropriateness of our non-employee director
compensation policy in light of our objectives described below, the compensation policy for our
non-employee directors for 2006 was recommended by our Compensation Committee and approved by our
Board of Directors. This policy was designed to fairly pay our directors for work required for a
company of our size, scope and complexity, be competitive within an appropriate peer group, and
incorporate an equity component to help align our directors interests with the long-term interests
of our stockholders. We also have adopted stockownership guidelines for our directors to further
promote this alignment of interests, which are summarized above under Compensation Discussion and
Analysis Stock Ownership/Retention Guidelines, and can be found in our corporate governance
guidelines. The Compensation Committee also utilized the assistance of the compensation consultant
for 2006, CRI, in designing and reviewing our 2006 non-employee director compensation policy, in
particular with respect to the collection of peer group director compensation data.
The compensation policy for our non-employee directors for 2006 was as follows:
Each non-employee board member (other than the Chairman of the Board) serving on the Board of
Directors after the 2006 annual stockholder meeting was paid an annual retainer of $18,000 (payable
quarterly in arrears). Each member of the Audit Committee (other than the Chair) received an
additional annual retainer of $10,000 (payable quarterly in arrears). The Chairman of the Board of
Directors was paid a monthly retainer of $10,000. The Chairs of the Audit Committee and Executive
Committee of the Board of Directors were paid an additional annual retainer of $20,000 (payable
quarterly in arrears). The Chairs of the Compensation and Nominating and Corporate Governance
Committees of the Board of Directors were paid an additional annual retainer of $10,000 (payable
quarterly in arrears).
Each non-employee board member additionally received the following fees for attendance at
Board and committee meetings, as applicable: (i) $2,000 for each board meeting attended in person
or via telephone; (ii) $500 for each committee meeting (other than an Audit Committee or Executive
Committee meeting) attended in person or via telephone, to the extent not held in conjunction with
a full Board meeting; and (iii) $1,000 for each Audit Committee meeting attended in person or via
telephone, to the extent not held in conjunction with a full Board meeting.
Non-employee board members received annual restricted stock grants as follows. Each Board
member (other than the Chairman of the Board, the Audit Committee members and the Chair of the
Executive Committee) received an annual grant of 4,500 shares of restricted common stock. The
Chairman of the Board received an annual grant of 18,000 shares of restricted common stock. Each
Audit Committee member (other than the Chair) received an annual grant of 6,500 shares of
restricted common stock. The Chair of the Audit Committee received an annual grant of 8,500 shares
of restricted common stock. The Chair of the Executive Committee received an annual grant of 8,500
shares of restricted common stock. The restricted shares were issued pursuant and subject to the
terms of the Companys 2000 Plan and the form of award agreement previously filed with the SEC and
vest one year from the date of grant.
In addition, non-employee directors are reimbursed for reasonable expenses incurred to attend
Board and committee meetings and other Company-related business meetings if a Board members
presence is requested, as well as director education programs.
Our director who is also an employee (Mr. Balthrop) received no additional compensation for
his services as a director for 2006.
Subject to ratification by our full Board of Directors, the Compensation Committee has
recommended that the cash compensation for our non-employee directors remain unchanged for 2007,
except that the committee has recommended that the cash retainer for the Compensation Committee
chair should be raised to $15,000. In addition, the Compensation Committee has recommended,
subject to Board ratification, that the equity award policy for 2007 be revised as follows.
Each Board member (other than the Chairman of the Board, the Audit Committee members and the
Chair of the Executive Committee) shall receive an annual grant of shares of restricted common
stock with a fair market value of $70,000 on the date of grant (based on the closing
price of the Companys common stock as reported on the
33
NASDAQ Global Market on the date of grant, without discount as a result of the restrictions on such
shares). The Chairman of the Board shall receive an annual grant of shares of restricted common
stock with a fair market value of $200,000 on the date of grant. Each Audit Committee Member
(other than the Chair) shall receive an annual grant of shares of restricted common stock with a
fair market value of $100,000 on the date of grant. The Chair of the Audit Committee shall receive
an annual grant of shares of restricted common stock with a fair market value of $110,000 on the
date of grant. The Chair of the Executive Committee shall receive an annual grant of shares of
restricted common stock with a fair market value of $100,000 on the date of grant. The Chair of
the Nominating and Corporate Governance Committee shall receive an annual grant of shares of
restricted common stock with a fair market value of $80,000 on the date of grant.
The foregoing equity grants are intended to be without duplication and it is intended that
each Board member shall be entitled to the equity grant with the highest applicable value pursuant
to the equity compensation policy listed above. The restricted shares shall be issued pursuant and
subject to the terms of the Equity Plan and the form of award agreement previously approved by the
Compensation Committee, and shall vest one year from the date of grant.
The Compensation Committee intends to reassess our non-employee director compensation policy
over the course of 2007 with the assistance of its current compensation consultant, Hewitt.
34
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information known to us regarding the ownership of the
common stock of the Company as of the record date (except as otherwise indicated below) by (i) each
director and director nominee, (ii) each named executive officer, (iii) all directors and executive
officers as a group and (iv) each person known to us to own beneficially 5% or more of our
outstanding common stock.
The information set forth below includes shares of common stock directly and indirectly owned
and shares of common stock underlying currently exercisable options, as well as those options which
will become exercisable within 60 days of April 11, 2007. Except as otherwise indicated, the named
persons below have sole voting and dispositive power with respect to beneficially owned shares.
|
|
|
|
|
|
|
|
|
|
|
Common Stock Beneficially Owned |
|
|
|
|
|
|
Total as a |
|
|
Number of Shares |
|
Percentage of |
Beneficial Owner |
|
Owned (1) |
|
Shares Outstanding |
Directors and Named Executive Officers (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
G. Walter Loewenbaum II (3) |
|
|
1,803,923 |
|
|
|
5.1 |
% |
Fred C. Goad, Jr. (4) |
|
|
280,700 |
|
|
|
* |
|
Jim D. Kever (5) |
|
|
159,866 |
|
|
|
* |
|
Robert J. Cresci |
|
|
220,516 |
|
|
|
* |
|
Kevin M. McNamara |
|
|
109,666 |
|
|
|
* |
|
Thomas W. Erickson |
|
|
283,666 |
|
|
|
* |
|
Jay Johnston (6) |
|
|
77,000 |
|
|
|
* |
|
Gerard Vaillant |
|
|
39,000 |
|
|
|
* |
|
J. Stark Thompson |
|
|
11,000 |
|
|
|
* |
|
Patrick J. Balthrop, Sr. |
|
|
701,309 |
|
|
|
2.0 |
% |
Harriss T. Currie |
|
|
258,589 |
|
|
|
* |
|
Randel S. Marfin |
|
|
277,675 |
|
|
|
* |
|
James W. Jacobson, Ph.D. |
|
|
86,292 |
|
|
|
* |
|
David S. Reiter |
|
|
176,371 |
|
|
|
* |
|
All directors and executive officers
as a group (17 persons) |
|
|
4,778,831 |
|
|
|
13.5 |
% |
|
|
|
|
|
|
|
|
|
Other 5% Stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
St. Denis J. Villere & Company, LLC (7) |
|
|
5,044,578 |
|
|
|
14.3 |
% |
210 Baronne Street, Suite 808
New Orleans, LA 70112 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Barclays Global Investors, N.A. (8) |
|
|
1,973,372 |
|
|
|
5.6 |
% |
45 Fremont Street
San Francisco, CA 94105 |
|
|
|
|
|
|
|
|
|
|
|
* |
|
Less than 1%. |
|
(1) |
|
Includes shares attributable to shares of common stock not outstanding but subject to
currently exercisable options (as well as those options which will become exercisable within
60 days of April 11, 2007) as follows: Mr. Loewenbaum 100,000 shares; Mr. Goad 10,000
shares; Mr. Kever 45,200 shares; Mr. Cresci 45,200 shares; Mr. McNamara 95,000 shares;
Mr. Erickson 262,500 shares; Mr. Johnston 15,000 shares; Mr. Vaillant 15,000 shares; Mr.
Thompson 0 shares; Mr. Balthrop 375,008 shares; Mr. Currie 197,028 shares; Mr. Marfin
239,375 shares; Dr. Jacobson 48,437 shares; Mr. Reiter 138,096 shares; and all directors
and executive officers as a group 1,764,658 shares. |
|
(2) |
|
The applicable address for all directors and named executive officers is c/o Luminex
Corporation, 12212 Technology Boulevard, Austin, Texas 78727. |
35
|
|
|
(3) |
|
Does not include 1,007,422 shares held by Mr. Loewenbaums wife, Lillian Loewenbaum;
208,998 shares held by trusts for the benefit of
Mr. Loewenbaums descendants of which Lillian
Loewenbaum is the trustee; and 127,472 shares held by a trust for the benefit of Mr.
Loewenbaum which has an independent trustee and over which Mr. Loewenbaum neither has nor
shares investment or voting power. |
|
(4) |
|
Includes 4,810 shares held by a trust of which Mr. Goad is the trustee. Mr. Goad disclaims
beneficial ownership of the shares held by the trust. |
|
(5) |
|
Does not include 51,212 shares held by a trust for the
benefit of Mr. Kevers children. Mr. Kever disclaims
beneficial ownership of the shares held by the trust. |
|
(6) |
|
Includes 8,000 shares held by JK Investments II, a limited partnership managed by Mr.
Johnston and his wife and of which a trust for the benefit of Mr. Johnstons children is the
limited partner. |
|
(7) |
|
This information is as of December 31, 2006, and is based solely on a Schedule 13G/A filed by
St. Denis J. Villere & Company on April 4, 2007. St. Denis J. Villere & Company is an
investment advisor registered under Section 203 of the Investment Advisors Act of 1940 and
reports sole voting and dispositive power as to 799,073 shares and shared voting and
dispositive power as to 4,245,505 shares. |
|
(8) |
|
This information is as of December 31, 2006, and is based solely on a Schedule 13G filed by
Barclays Global Investors, N.A. on January 23, 2007. Barclays Global Investors, N.A. is a
Bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934 and reports sole
voting power as to 1,859,011 shares and shared voting and dispositive power as to 114,361
shares. |
36
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Since the beginning of the last fiscal year, we are aware of no related party transactions
between us and any of our directors, executive officers, 5% stockholders or their family members
which require disclosure under Item 404 of Regulation S-K under the Securities Exchange Act of
1934.
We have adopted a related party transaction policy, administered by our Audit Committee, that
requires the Audit Committee (or the chair of the Audit Committee in certain instances with respect
to de minimus transactions) to review and either ratify, approve or disapprove all Interested
Transactions, subject to certain exceptions for specified pre-approved transactions not believed
to create a material interest with respect to Related Party. Interested Transactions are
generally defined to include any transaction, arrangement or relationship or series of similar
transactions, arrangements or relationships (including any indebtedness or guarantee of
indebtedness) in which:
|
|
|
the aggregate amount involved exceeded, or will or may be expected to exceed, $100,000
in any calendar year; |
|
|
|
|
the Company was, is or will be a participant; and |
|
|
|
|
any Related Party had, has or will have a direct or indirect interest. |
For purposes of the policy, a Related Party is any:
|
|
|
person who is or was (since the beginning of the last fiscal year for which the Company
has filed a Form 10-K and proxy statement, even if they do not presently serve in that
role) an executive officer, director or nominee for election as a director; |
|
|
|
|
greater than 5% beneficial owner of the Companys common stock; |
|
|
|
|
immediate family member of any of the foregoing; or |
|
|
|
|
firm, corporation or other entity in which any of the foregoing persons is employed or
is a general partner, managing member or principal or in a similar position or in which
such person has a 10% or greater beneficial ownership interest. |
In determining whether to approve or ratify an Interested Transaction under the policy, the
Audit Committee is to consider all relevant information and facts available to it regarding the
Interested Transaction and take into account factors such as the Related Partys relationship to
the Company and interest (direct or indirect) in the transaction, the terms of the transaction and
the benefits to the Company of the transaction. No director is to participate in the approval of an
Interested Transaction for which he or she is a Related Party or otherwise has a direct or indirect
interest.
In addition, the Audit Committee is to review and assess ongoing Interested Transactions, if
any, on at least an annual basis to determine whether any such transactions remain appropriate or
should be modified or terminated.
Our related party transaction policy has been incorporated into our Code of Compliance, which
can be viewed at the Investor Relations section of our website at www.luminexcorp.com.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Under the securities laws of the United States, our directors, executive officers and any
persons holding more than ten percent of our common stock are required to report their initial
ownership of our common stock and any subsequent changes in their ownership to the SEC. Specific
due dates have been established by the SEC, and we are required to disclose in this Proxy Statement
any failure of such persons to file by those dates. Based solely upon the copies of Section 16(a)
reports that we have received from such persons for their transactions in 2006 and written
representations to the Company that we have received such persons that no other reports were
required, we believe that there has been compliance with all Section 16(a) filing requirements
applicable to such directors, executive officers and ten-percent beneficial owners for 2006.
37
EXPENSES AND SOLICITATION
We will bear the cost of soliciting proxies. Proxies may be solicited in person or by
telephone, facsimile, electronic mail or other electronic medium by certain of our directors,
officers and regular employees, without additional compensation. The Company requests that
brokerage houses and other custodians, nominees and fiduciaries forward solicitation materials to
the beneficial owners of shares of the Companys common stock held of record by such persons, and
the Company will reimburse such brokers and other fiduciaries for their reasonable out-of-pocket
expenses incurred when the solicitation materials are forwarded.
STOCKHOLDER PROPOSALS FOR 2008 ANNUAL MEETING
It is contemplated that our 2008 annual meeting of stockholders will take place in May 2008.
Stockholders proposals will be eligible for consideration for inclusion in the proxy statement for
the 2008 annual meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 if such
proposals are received by us before the close of business on December 26, 2007. Notices of
stockholders proposals submitted outside the processes of Rule 14a-8 will be considered timely
(but not considered for inclusion in our proxy statement), pursuant to the advance notice
requirement set forth in our bylaws, if such notices are filed with our Secretary not less than 30
days nor more than 90 days prior to the first anniversary of the Meeting in the manner specified in
the bylaws. For proposals that are not timely filed, we retain discretion to vote proxies that we
receive. For proposals that are timely filed, we retain discretion to vote proxies that we receive
provided (1) we include in our proxy statement advice on the nature of the proposal and how we
intend to exercise our voting discretion and (2) the proponent does not issue a proxy statement.
In order to curtail any controversy as to the date on which a proposal was received by us, we
suggest that stockholders submit their proposals by certified mail, return receipt requested.
TRANSACTION OF OTHER BUSINESS
At the date of this Proxy Statement, the only business which the Board of Directors intends to
present or knows that others will present at the Meeting is as set forth above. If any other
matter or matters are properly brought before the Meeting, or an adjournment or postponement
thereof, it is the intention of the persons named in the accompanying form of proxy to vote the
proxy on such matters in accordance with their best judgment.
UPON WRITTEN REQUEST OF ANY STOCKHOLDER TO DAVID REITER, CORPORATE SECRETARY, LUMINEX
CORPORATION, 12212 TECHNOLOGY BOULEVARD, AUSTIN, TEXAS 78727, THE COMPANY WILL PROVIDE WITHOUT
CHARGE A COPY OF THE COMPANYS ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2006, AS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Austin, Texas
April 23, 2007
38
REVOCABLE PROXY
LUMINEX CORPORATION
12212 Technology Blvd., Austin, Texas 78727
THIS PROXY IS BEING SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF LUMINEX CORPORATION
FOR USE ONLY AT THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 24, 2007 AND AT ANY ADJOURNMENT OR POSTPONEMENT THEREOF.
The undersigned hereby appoints Harriss T. Currie and David S. Reiter, or
either of them, or any successors in their respective positions, as proxies with
full powers of substitution, and hereby authorizes them to represent the undersigned
and to vote, as designated on the reverse side, all the shares of common stock of
Luminex Corporation (the Company) held of record by the undersigned as of April
11, 2007, at the Annual Meeting of Stockholders (the Annual Meeting) to be held at
the Hilton Austin Airport Hotel, 9515 New Airport Drive, Austin, Texas 78719 on
Thursday, May 24, 2007, at 12:00 p.m. local time, or at any adjournment or
postponement thereof.
The Board of Directors recommends a vote FOR the Boards Class I Director
nominees and FOR the ratification of the appointment of Ernst & Young LLP as the
Companys independent registered public accounting firm for fiscal 2007. Shares of
common stock of the Company will be voted as specified. If not otherwise specified,
this proxy will be voted FOR the election of the Board of Directors Class I
Director nominees to the Board of Directors, FOR the ratification of the
appointment of Ernst & Young LLP as the Companys independent registered public
accounting firm for fiscal 2007, and on other matters properly presented at the
Annual Meeting or any postponement or adjournment thereof, at the discretion of the
proxies. You may revoke this proxy at any time prior to the time it is voted at the
Annual Meeting in the manner described in the Proxy Statement. This proxy may not be
voted for any person who is not a nominee of the Board of Directors of the Company.
The undersigned hereby acknowledges receipt of a Notice of Annual Meeting of
Stockholders of Luminex Corporation to be held on May 24, 2007, a Proxy Statement
for the Annual Meeting and the 2006 Annual Report, prior to the signing of this
proxy. All of the proposals set forth on the reverse side hereof are more fully
described in the Proxy Statement.
(Continued, and to be dated and signed, on reverse side)
|
|
|
|
Address Change/Comments (Mark the
corresponding box on the reverse side) |
|
|
|
|
|
|
|
|
|
|
|
5 FOLD
AND DETACH
HERE 5
You can now access your Luminex Corporation account online.
Access
your Luminex Corporation stockholder account online via Investor
ServiceDirect
® (ISD).
Mellon Investor Services LLC,
Transfer Agent for Luminex Corporation, now makes it easy and convenient to get current information on your stockholder account.
|
|
|
|
|
|
|
|
|
|
|
|
|
View account status
|
|
|
|
View payment history for dividends
|
|
|
|
|
View certificate history
|
|
|
|
Make address changes |
|
|
|
|
View book-entry information
|
|
|
|
Obtain a duplicate 1099 tax form |
|
|
|
|
|
|
|
|
Establish/change your PIN |
Visit us on the web at http://www.melloninvestor.com
For Technical Assistance Call 1-877-978-7778 between 9am-7pm
Monday-Friday Eastern Time
Investor
ServiceDirect®
is a registered trademark of Mellon Investor Services
LLC
****TRY IT OUT****
www.melloninvestor.com/isd/
Investor
ServiceDirect ®
Available 24 hours per day, 7 days per week
|
|
|
TOLL FREE NUMBER:
|
|
1-800-370-1163 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Please
Mark Here
for Address
Change or
Comments
|
|
o |
|
|
|
|
|
|
|
|
SEE REVERSE SIDE |
|
|
1. |
|
Proposal to elect the following nominees as Class I directors for a three-year term:
01 Robert J. Cresci
02 Thomas W. Erickson 03 Gerard Vaillant |
|
|
|
FOR ALL NOMINEES
|
|
WITHHOLD |
(except if written below)
|
|
ALL |
o
|
|
o |
(Instruction: to withhold authority to vote for an
individual nominee, write that nominees name in the space provided below.)
|
|
|
|
|
|
|
|
|
2.
|
|
Proposal to
ratify the appointment of Ernst & Young LLP as the Companys
independent registered public accounting firm for fiscal 2007.
|
|
FOR
o
|
|
AGAINST
o
|
|
ABSTAIN
o |
|
|
|
|
|
|
|
|
|
3.
|
|
In their discretion, the proxies are authorized to vote with
respect to matters incident to the conduct of the Annual Meeting, or on any other matter that may properly
come before the Annual Meeting or any postponement or adjournment thereof.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Mark X in only one box) |
|
|
|
|
|
|
|
|
|
I plan to attend the meeting. |
|
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature:
|
|
|
|
Date:
|
|
|
, |
2007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Please sign exactly as your name(s) appear(s) on this proxy.
When signing in a representative capacity, please give title. When shares are held jointly, each person should sign.
|
WE ENCOURAGE YOU TO TAKE ADVANTAGE OF INTERNET OR TELEPHONE VOTING,
BOTH ARE AVAILABLE 24
HOURS A DAY, 7 DAYS A WEEK.
Internet
and telephone voting is available through 11:59 PM Eastern Time
the
day prior to annual meeting day.
Your Internet or telephone vote authorizes the named proxies to vote your shares in the same manner
as if you marked, signed and returned your proxy card.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INTERNET
|
|
|
|
|
|
TELEPHONE
|
|
|
|
|
|
|
|
|
http://www.proxyvoting.com/lmnx
|
|
|
|
|
|
1-866-540-5760
|
|
|
|
|
|
|
|
|
Use the Internet to vote your proxy.
Have your proxy card in hand when
you access the web site.
|
|
|
OR
|
|
|
Use any touch-tone telephone to
vote your proxy. Have your proxy
card in hand when you call.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
If you vote your proxy by Internet or by telephone, you do NOT need to mail back your proxy
card. To vote by mail, mark, sign and date your proxy card and return it in the enclosed
postage-paid envelope.
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
Choose MLinkSM
for fast, easy and secure 24/7 online access to your future proxy
materials, investment plan statements, tax documents and more. Simply log on to Investor ServiceDirect®
at www.melloninvestor.com/isd where step-by-step instructions will prompt you
through enrollment.
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
| |